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ABSTRACT 
 
Pereskia bleo (Kunth) belongs to the family of Cactaceae and locally known as 
jarum tujuh bilah. It has been used traditionally by native Malaysian for the treatment of 
diabetes. However, the lack of scientific data to validate such claim have motivates 
researcher to study for its anti-diabetic activities. In this study, the leaves, stems and roots 
of Pereskia bleo crude extracts were extracted with hexane, petroleum ether, chloroform, 
methanol and aqueous. The separation and detections of bioactive compounds were done 
using Thin Layer Chromatography (TLC) and Liquid Chromatography Mass spectrometry 
combined with Mass Spectrometry (LCMS/MS) methods. The TLC results showed the 
presence of terpenoid, alkaloid, phenolics acid and flavonoids in Pereskia bleo crude 
extracts. While in LCMS/MS analysis has revealed the presence of phenolics acid, amino 
acid, jasmonic acid or dihydroxymellein, Chrysin, Apigenin based compounds, Apigenin 6 
C Glucoside, and Apigenin 7 Rutinoside in Pereskia bleo crude extracts. The total phenol 
content were highest in stem aqueous extract, root chloroform extract and leaves methanol 
extract at 6.06+0.1 mg GAE/g, 3.64+0.1 mg GAE/g and 3.00+0.1 mg GAE/g respectively. 
Whereas, the total flavonoids content were highest in stems , leaves and root chloroform 
extract at 11.07+0.7 mg QE/g, 5.2+0.7 mg QE/g  and 3.40+0.7 mg QE/g respectively. The 
Glycogen Phosphorylase Inhibition bioassay (GPi) showed the highest percentage of GPi 
activity from roots, leaves and stems methanol extract of Pereskia bleo at 89.9%, 82.3% 
and 78.3% respectively. The acute toxicity test was performed using non-diabetic Sprague 
Dawley (SD) rats have showed none of the toxic signs occur such as anxiety, urination or 
defecation, pain response and death when administrated with 250, 500 and 1000mg/kg of 
Pereskia bleo aqueous extract. In Oral Glucose Tolerance Test (OGTT), the administration  
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of Pereskia bleo aqueous extracts showed the improved of glucose tolerance in non-
diabetic rats. The roots aqueous extracts of Pereskia bleo also showed a maximum 
reduction of blood glucose level when administered with 250mg/kg and 500mg/kg at 120 
minutes with 20% and 21%. Followed by leaves and stem aqueous extracts of Pereskia 
bleo with 11% and 14% of reduction, respectively. In treatments of diabetic rats, the 
alloxan-induced diabetic rats showed that 500mg/kg of the leaves, stems and roots aqueous 
extracts of Pereskia bleo showed the significantly reduction in fasting plasma glucose 
levels by 66%, 65 and 58% (p<0.05) respectively on 25th day compared to diabetic control 
group. The treatments of Pereskia bleo aqueous extracts to diabetic rats showed the 
significantly (p<0.05) improved in body weight and decreased in liver enzymes levels 
(ALT, AST and ALP), renal function test (creatinine and urea) and serum lipid profile 
(Total cholesterol, triglyceride, LDL) compared to diabetic group. It is also showed a 
significantly (p<0.05) increased in HDL levels compared to diabetic group. Thus, this study 
discovered that bioactive compounds found in crude extract of Pereskia bleo might be 
useful as anti-hyperglycaemic agents and these finding might be a fundamental to the 
further research to prove the claimed made by traditional practitioner that has consumed 
Pereskia bleo as diabetes treatment. 
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ABSTRAK 
 
Pereskia bleo ( Kunth ) terdiri daripada famili Cactaceae dan dikenali oleh 
masyarakat tempatan sebagai pokok ' Jarum tujuh bilah ' . Ia telah digunakan secara 
tradisional oleh orang melayu dalam rawatan penyakit diabetis. Walau bagaimanapun, 
kekurangan data saintifik untuk mengesahkan dakwaan ini telah menggalakkan penyelidik 
untuk mengkaji aktiviti anti-diabetis pokok ini. Dalam kajian ini ekstrak mentah daun, 
batang dan akar Pereskia bleo ini diekstrak dengan heksana, petroleum eter, kloroform, 
metanol dan akues. Pengasingan dan pengesanan sebatian bioaktif telah dilakukan dengan 
menggunakan kaedah Thin Layer Chromatography (TLC) dan Liquid Chromatography 
Mass Spectrometry bergabung dengan Massa spektrometri (LCMS/MS). Keputusan TLC 
menunjukkan kehadiran terpenoid, alkaloid , asid phenolic dan flavonoid di dalam Pereskia 
bleo ekstrak mentah. Manakala di dalam analisis LCMS/MS telah mengesan kehadiran asid 
fenolik, asid amino, asid jasmonic atau dihydroxymellein, Chrysin, sebatian berasaskan 
apigenin, apigenin 6 C Glucoside, dan apigenin 7 Rutinoside di dalam ekstrak mentah 
Pereskia bleo. Jumlah kandungan fenol paling banyak di batang ekstrak akueus, ekstrak 
kloroform akar dan ekstrak methanol daun pada 6.06+0.1 mg GAE/g, 3.64+0.1 mg GAE/g 
dan 3.00+0.1 mg GAE/g, masing-masing. Manakala jumlah kandungan flavonoid yang 
paling tinggi di dalam ekstrak kloroform batang, daun dan akar pada 11.07+0.7 mg QE/g , 
5.2+0.7 mg QE/g dan 3.40+0.7 mg QE/g masing-masing. Ujian bioesei Glikogen 
Phosphorylase Perencatan (GPI) menunjukkan peratusan yang tertinggi aktiviti GPI adalah 
dari ekstrak metanol akar, daun dan batang Pereskia bleo, dengan masing-masing 89.9%, 
82.3% dan 78.3%. Ujian ketoksikan akut telah dilakukan dengan menggunakan tikus 
Sprague Dawley (SD) bukan diabetis telah menunjukkan tiada tanda-tanda toksik yang 
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berlaku seperti keresahan, kencing atau membuang air besar, tindak balas kesakitan dan 
kematian apabila diberi dengan 250, 500 dan 1000mg/kg ekstrak akueus Pereskia bleo. Di 
dalam Toleransi Glukosa Oral Test (OGTT), ekstrak akueus Pereskia bleo menunjukkan 
toleransi glukosa yang baik pada tikus bukan diabetis. Akar ekstrak akueus Pereskia bleo 
juga menunjukkan pengurangan maksimum tahap glukosa darah apabila diuji dengan dos 
250mg/kg dan 500mg/kg pada 120 minit dengan 20% dan 21%. Diikuti dengan daun dan 
batang ekstrak akueus Pereskia bleo dengan 11% dan 14%, masing-masing. Manakala di 
dalam rawatan ke atas tikus diabetis, pada dos 500mg/kg daun, batang dan akar ekstrak 
akueus Pereskia bleo menunjukkan pengurangan paras glukosa plasma puasa signifikan (p 
< 0.05)  sebanyak 66% , 65% dan 58%, masing-masing pada hari-hari ke-25 berbanding 
dengan kumpulan kawalan diabetis. Rawatan dengan ekstrak akueus Pereskia bleo kepada 
tikus diabetis menunjukkan peningkatan yang signifikan (p < 0.05) pada berat badan dan 
pengurangan di dalam paras enzim hati (ALT, AST dan ALP), ujian fungsi buah pinggang 
(creatinine dan urea) dan profil lipid serum (Jumlah kolesterol, trigliserida, LDL) 
berbanding dengan kumpulan diabetis. Ia juga menunjukkan peningkatan yang signifikan 
(p < 0.05) di dalam paras HDL berbanding dengan kumpulan diabetis. Oleh itu, kajian ini 
mendapati bahawa sebatian bioaktif yang terdapat dalam ekstrak mentah daripada Pereskia 
bleo mungkin berguna sebagai agen anti- hyperglyceamic dan penemuan ini mungkin 
menjadi asas kepada penyelidikan lebih lanjut untuk membuktikan tuntutan yang telah 
dibuat oleh pengamal tradisional yang menggunakan Pereskia bleo di dalam rawatan 
diabetes . 
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Diabetes mellitus or generally known as diabetes is one of the chronic disorder. It is 
occurred either because of lack of insulin production by the pancreas or the insulin cannot 
be used by our body effectively. Various complications developed due to the effect of 
metabolism dysfunction in diabetes, (Auslander et al., 2002) including the damage to the 
heart, kidney, blood vessels, eyes and nerves. Therefore, diabetes is categorized as a third 
killing disease after cancer and cardiovascular disease (Li et al., 2004). Diabetes and its 
complications have a significant economic impact on health system as well as to families 
and countries. There are no medications that can cure this disorder. However with a proper 
diet, exercise, and use of appropriate medications such as oral medications and insulin, 
blood glucose can be manage close to normal level without causing hypoglycaemia. The 
oral medications varies with their classes, depends on the type of diabetes, ages, the 
individual itself and other factors. Many research has been done on finding the treatment of 
diabetes thus lead to the synthesis of oral medications, still, the medications were found to 
cause side effects (Fowler,  2007). As a result, these serious side effects have been reported 
worldwide (WHO, 2002). Therefore, studies of medicinal plant has been a great interest 
among researcher as these herbs were claimed to be safe, low cost and effective, hence 
suitable to be used as one of the alternative treatment (Pari et al., 1999).  
 
The Pereskia bleo (Kunth) DC tree is a species belongs to the botanical family of 
Cactaceae (Tan et al., 2004).  It is commonly known as “jarum tujuh bilah” or “pohon 
jejarum” by Malaysian. This species was believed as the origin of other cacti. They are the 
only cactus genus that has a persistent non-succulent leaves. This species may grow to 7 
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meter high. Pereskia bleo has thinner, corrugated leaves, and oranges-red flower with 
shorter spines. 
 
A preliminary survey were done to study the effectiveness of Pereskia bleo 
consumed by villagers in Kelantan, Malaysia that was reported that this plant was used as a 
health supplement, cancer treatment, muscular ache, hypertension, diabetes mellitus, 
internal problem, cyst and treating boils (Khor et al., 2013). It was verified by various 
studies reported that this plant has anti-tumours, anti-rheumatic, anti-ulcer, anti-
inflammatory activities (Sim et al., 2010; Tan et al., 2004). Furthermore, Pereskia bleo can 
be eaten raw as it was found to be non-toxic (Sim et al., 2010). However, there are no 
scientific data reported regarding the anti-diabetic agents from this plant. 
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2.1 Diabetes Mellitus 
 
Diabetes mellitus is a common chronic disorder. It is characterized by 
hyperglycaemia (high blood glucose level)c due to carbohydrate metabolism disorder 
with an insulin deficiency or insulin resistance or both (Anonymous, 2009). This 
disease is a third killer disease, after cancer and cardiovascular disease (Li et al., 
2004). It is the most prevalent metabolic disorder for all age-group in the world 
(Saladin, 2010). The World Health Organizations (WHO) has characterized this 
disorder as pandemic due to the spread of diabetes globally. It is about more than 347 
million people of worldwide were estimated to have diabetes (Danaei et al., 2011). In 
2005, 1.1 million people were estimated to die from diabetes and almost 80% of them 
are from low and middle-income countries (Mathers et al., 2006). Furthermore, 50% of 
them are people at age 70 years, while 55% of deaths case was women. Total of death 
in the next 10 years are projected to rise more than 50%. By the year 2030, WHO has 
predicted that this disorder will become the seventh leading cause of death.  
 
The untreated diabetes mellitus can cause many complications. Acute 
complications are characterized by elevated blood glucose level (hyperglycaemia) and 
abnormally low blood glucose level due to medications. While chronic complications 
are characterized by diabetes with kidney, eyes, heart, nerves and feet damage. 
Diabetes is associated with cardiovascular disease. Patients with diabetes  have a risk to 
suffer from heart disease and stroke. About 50% of diabetes patients has died due to 
cardiovascular disease (Candido et al., 2003; Morrish et al., 2001). Patients with 
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diabetes mainly type 2 diabetes are often have unhealthy cholesterol level including 
high LDL-cholesterol (Grundy et al., 1990), high triglyceride and low HDL-
cholesterol. In addition, the decreased in body weight and insulin concentrations due to 
diabetes may lead to increasing of cardiovascular risk. Lipid profiles have been used as 
an indicator of cardiovascular disease (Huang et al., 1988). It has showed a correlation 
between increasing in plasma LDL-cholesterol, total cholesterol and the risk to have 
heart disease (Kamisah et al., 2005). Type 2 diabetes associated with alteration in 
plasma lipid and lipoproteins are recognized as predictor for coronary heart disease 
(Craig et al., 1998; Otamere et al., 2011). Previous study reported that the inhibition of 
GP cause the reduction of lipid parameter such as total cholesterol and triglyceride 
level (Jasem et al., 2012; Parthiban et al., 2013). Diabetes mellitus associated with 
lipid changed, has attributed to an increasing of fatty acid flux into liver. The 
accumulation of fatty acid are converted to triglycerides, thus reduce the level of HDL-
cholesterol and increase in small dense of LDL-cholesterol (Mbaka et al., 2012; 
Mooradian, 2009; Shih et al., 1997). 
 Liver is a big organ that has a main function in managing carbohydrate, lipids, and 
protein metabolism. Liver disease occurred as consequences of diabetes mellitus. It is one 
of the main causes of death in type 2 diabetes. The death risk cause by liver disease is 
higher compared to the risk cause by cardiovascular disease (Ragavan et al., 2006). 
Previous study reported that diabetes caused by to alloxan administration has deleterious 
effects on liver and kidneys (Giannini et al., 2005). The increased in hepatic glucose due to 
glycogenolysis or glyconeogenesis was detected by hepatic enzyme; alanine 
aminotransaminase (ALT), serum aspartate aminotransaminase (AST) and alkaline 
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phosphatase (ALP) (Nahla et al., 2012; Rawi et al., 1998; Shibib et al., 1993; WHO, 2002). 
The activities of these hepatic enzymes were used as marker to observe any damage in liver 
tissue (Eze et al., 2012; Ravikumar et al., 2010; Uboh et al., 2010), organ and body. The 
damage in liver function is demonstrated with the increasing of ALT and AST (Zafar et al., 
2009). In alloxan-induced diabetes, the damage of β-cells cause the reduction in insulin 
produced, leads to organelles injury, thus released ALT and AST (Muhammad et al. , 2008; 
Sallie et al., 1991; Senthil et al., 2003).  
 
Diabetes also associated with diabetic nephropathy. It caused damage to the 
kidney which can lead to chronic renal failure (Nelson et al., 1995; Olimpia et al., 
2005). It is most likely to develop in diabetes type 1 compared to diabetes type 2. The 
kidney acts as a filter of the blood and removes wastes from the blood. The damage 
occurred in blood vessel walls of kidney filter due to prolong diabetes, initially will 
become leaking to larger protein such as albumin. Previous study shows that the 
treatment of diabetes by controlling their blood glucose level and blood pressure may 
prevent onset of chronic renal failure (Micheal et al., 2005). Urea and creatinine are 
the parameters in diagnosis of kidney functions. The increase in creatinine and urea 
level indicates the dysfunction of kidney (Alagammal et al., 2012; Almdal et al., 1988; 
Kakadiya et al., 2010). 
 
Other complications that occur due to diabetes are diabetic retinopathy and 
diabetic neuropathy. Diabetic retinopathy is a damage of blood vessel in retina of the 
eye. This damage can lead to visual symptoms, reduce in vision, and potentially 
  
 
6 
 
become blindness. About 80% of patients who had diabetes more than 10 years will be 
affected by this disease (Eliott, 2007). While diabetic neuropathy is damage that occurs 
in nervous system, mostly cause numbness, pain in feet and skin damage. This disease 
has affected about 131 million people in 2010 which is 1.9% of the world population 
(Vos, 2012). 
 
2.1.1 Type 1 Diabetes 
 
Type I diabetes was also known as childhood-onset diabetes, insulin-dependent, or 
juvenile. It is characterized by lacking of insulin production cause by the failure of the 
pancreatic beta cells. It can also occur due to damage of pancreas by disease, alcohol or 
surgery. Most patient developed this type of diabetes are healthy, and it was termed as 
juvenile as the majority of the patients are children. Patients with type I diabetes have 
symptoms that includes weight loss, blurred vision, fatigue, frequent hunger and thirsty 
(polydipsia) and extremely urine discharge (polyuria). Diabetes type I occur because of 
some factors such as genetics, environmental, virus, diet and drugs (Knip et al., 2005). This 
type of diabetes is a polygenic disease, which is the disease that occurred because of 
contributions of multiple genes. It is depends on locus or combination of loci regardless it is 
dominant, recessive or in between. A newborn child with father or sibling having diabetes 
type 1 has a 10% risk to develop type 1 diabetes, 4% if the mother aged below 25 years old 
and 1% if the mother aged above 25 years old. Environmental factors including identical 
twin, where one of the twin had diabetes type 1, the other one had about 30-50% risk to 
develop diabetes type 1. While in diabetes caused by virus as a factor, diabetes type 1 also 
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had proposed as a virus-triggered autoimmune response that happened when the immune 
system attacks virus-effected cells along with beta cells in pancreas (Delisa et al., 2002). 
However, not everyone infected by this virus has developed type 1 diabetes. The other 
factor caused diabetes is diet where the antibodies against cow milk protein are found to 
influence the autoimmune response. Vitamin D at dose of 2000IU given during the first 
year of a child was found to cause a reduction about 80% in the risk of getting diabetes type 
1 later in life. Furthermore, a period of breastfeeding also known to be associated with this 
factor among Czech children (Hana et al., 2005). Other than that, the usage of drugs 
sometimes caused the destruction of the pancreatic cells. For examples, streptozotocin used 
as an antibiotic and antineoplastic agent in chemotherapy of pancreatic cancer, can kills 
beta cells. Trauma, pancreatitis or tumour also can lead to the fall in insulin productions. 
Type 1 diabetes can be treated with insulin, either via injection, pumps or inhaled of 
insulin. Other alternatives treatments are pancreatic transplants and pancreatic islet cell 
transplant 
 
2.1.2 Type 2 Diabetes 
 
Type II diabetes also known as non-insulin-dependent or adult-onset. Usually 
patients above 45 years old were suffered from this type of diabetes. It is a metabolic 
disorder and characterized by insulin resistance and insulin deficiency (Kumar et al., 2005). 
Insulin produces by beta cells of pancreas are important in regulating carbohydrate and fat 
metabolism in body. Insulin resistance is a condition which cells fails to response normally 
to insulin. Insulin worked as a glucose transporter, deliver glucose to cells in livers, skeletal 
muscles, and fat tissue to absorb glucose from blood in order to provide energy. Due to 
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insulin resistance, cells are unable to receive glucose, amino acid, and fatty acid. Thus, 
glucose levels in blood will rise. At least 90% of patients with diabetes suffered from 
diabetes type 2. It is increased over 50 years in parallel of obesity. In 2010, approximately 
285 million people suffered with these disease, compared to 30 million in 1985 (Smyth et 
al., 2006). Diabetes type 2 always associated with cardiovascular, blindness and kidney 
failure (Ripsin et al., 2009). Diabetes type 2 occurs because of some factors such as 
lifestyle, genetic factors (Ripsin et al., 2009; Riserus et al., 2009), diet, lack of sleep and 
development of foetal during pregnancy that altered DNA methylation (Christian et al., 
2010). It is usually controlled by proper diet, regular exercise (Raina et al., 2008), 
maintaining ideal body weight and oral medication. 
 
2.1.3 Gestational Diabetes 
 
Gestational diabetes (GDM) was recognized by occurrence of hyperglycaemia 
during pregnancy especially in third semester. It is due to changes in growth hormone 
and cortisol secretion, secretion of human placenta lactogen and insulinase. Human 
placenta lactogen is produced by placenta and affects fatty acids and glucose 
metabolism, thus promotes lipoysis and decreases glucose uptake. The insulinase is 
produced by placenta and facilitates the insulin metabolism. About 2-5% of pregnancy 
women may have this disease and will have normal blood glucose reading after baby 
delivery of baby (Gilmartin et al., 2008). However, 20-50% of affected women mostly 
will develop to type 2 diabetes in the future. Pregnancy women with previous history 
of macrosomia (birth weight more than 4000g), strong family history of diabetes, and 
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obesity have higher percentage to get GDM (Gilmartin et al., 2008). Other risks factors 
for GDM includes ethnic group with higher rate of type 2 diabetes, polycystic ovarian 
syndrome (PCOS), hypertension, history of spontaneous abortions and unexplained 
stillbirths, and age older than 25 years (Marion et al., 2008). 
 
Gestational diabetes can be diagnose during prenatal screening as glucose 
tolerance was not present or recognized (Beckmann et al., 2005). Untreated gestational 
diabetes can cause risks of some disorder including macrosomia (high birth weight), 
congenital cardiac, abnormality in central nervous system and skeletal muscle 
malformations to foetus or the mother. 
 
If untreated, it can cause seizures or still birth. The early treatment of GDM 
shows reducing in foetal complication such as macrosomia (‘fat’ baby). Macrosomia 
develops due to extra glucose that goes inside the placenta, thus cause baby’s pancreas 
to works harder in making extra insulin that will reduce the high blood glucose levels. 
Therefore, newborn baby tents to have very low blood glucose level at birth and 
breathing problems (Diabetes Malaysia, 2007). 
 
The treatment of GDM includes the management of glycaemia control (Marion et 
al., 2008) such as the quality nutritional intake daily (Jovanovic-Peterson et al., 1992), 
scheduled physical activity, daily blood glucose testing and insulin injections (Crowther et 
al., 2005). The uses of oral hypoglycaemic agent such as glyburide and metformin are 
recommended in management of GDM when diet alone was insufficient. Previous study of 
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comparison between metformin and insulin in GDM patient has showed that it did not vary 
in neonatal complication (Rowan et al., 2008). However, the less severe hypoglycaemia in 
infants and preterm birth were common in GDM women treated with metformin (Gilmartin 
et al., 2008). 
 
2.2 Carbohydrate Metabolism 
 
Carbohydrate metabolism indicates in many biochemical processes such as the 
formation, breakdown and interconversion of carbohydrate in living organism. Glucose is 
the most important carbohydrate. Glucose is a simple monosaccharide that is important in 
cell body as a source of energy and metabolic intermediate. It is selected due to its lower 
tendency that can react with the amino groups of protein that can cause a glycation. 
Glycation of protein or lipids is a result from covalent bonding of this substrate with sugar 
molecule such as fructose. It can destroy the function of many enzymes and leads to varies 
disease such as renal failure, blindness and peripheral neuropathy in diabetes mellitus 
(American Diabetes Association, 2010). 
 
Cells body need glucose for proper functions. Glucose metabolism is a process 
which converts glucose into energy cells needed which is glycogen. There are three 
hormones from pancreas that is important in blood glucose regulations which are insulin, 
glucagon and epinephrine. Insulin is released from pancreatic beta cells when blood 
glucose concentration in body is too high. These rises may be due to a few factors such as 
the speed up of breakdown of glucose by glycolisis, the increase in glycogen synthesis in 
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liver and skeletal muscle or the increase of synthesis of lipids and protein. Insulin is 
important in stimulating the conversion of glucose into glycogen in liver or muscles via 
glycogenesis. Insulin will keep the glycogen synthase which an active enzyme for 
glycogenesis, in active state (Alvin, 1970; Vickram et al., 2011). Insulin also important in 
inhibits the glycogen phosphorylase (Vickram et al., 2011). When glucose enters a cell 
from bloodstream, it will convert into glucose-6-phosphate by glucokinase or hexokinase. 
This both enzymes plays important roles in facilitates phosphorylation of glucose. Glucose-
6-phosphate then isomerized to glucose-1-phosphate and then attached to uridine 
diphosphate (UDP).In muscle cells, the degradation of glycogen provides an immediate 
source of G6P for glycolysis which is important to provide energy for muscle contraction. 
In liver cells, this process important for release glucose into bloodstream for other cells 
uses.  
 
In contrast, the glucagon and epinephrine are released from pancreatic alpha cells 
when blood glucose in body falls. It can be due to the slower glucose enter the cell, the 
faster in liver glycogen breakdown, the increase of gluconeogenesis in glucose synthesis to 
breakdown the lipids and protein, or accelerates of glucogenesis. These hormones stimulate 
the conversion of glycogen to glucose via glycogenolysis (Sowka et al., 2001) 
 
Glycolysis occurs when body needs glucose immediately to supply energy. The end 
products of this process are pyruvic acid and ATP. Pyruvic acid later converted to acetyl 
CoA then citric acid in citric acid cycle. During contraction of muscle, pryruvic acid is 
converted to lactic acid and converted back to pyruvic acid during rest time. The pyruvic 
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acid was then converted back to glucose via gluconeogenesis. However, if the body does 
not require glucose, it will be converted into glycogen via glycogenesis. 
 
 
Figure 2. 1 Glucose metabolisms mechanism  (Ophardt, 2003). 
 
Glycogen contains many types of glucoses, providing a quick source of glucose 
when body needed. Glycogen stored in liver is a main source of energy supply to body 
tissue. It is considered as a main buffer of blood glucose levels. A second source is stored 
in skeletal muscle. However, muscle lack of glucose-6-phophatase enzyme, thus not 
available to other tissues even though the total of glycogen stored in muscle in about twice 
from liver. Other minor storage of glycogen is in kidney and intestines. Brain used 75% of 
glucose consumption daily via aerobic pathway. Body obtains glucose directly either from 
amino acids and lactate or diet via gluconeogenesis. These sources either remain soluble in 
body fluids or stored as glycogen. 
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Figure 2. 2 Glycogen structure showing α-1,4- and β-1,6-glycosidic linkages. 
 
Approximately up to 120,000 glucose residue linked by α-(1,4)- and α-1,6)- 
glycosidic bonds in glycogen. These links are occurred in every 8-12 of glucose residues. 
The branches occurred between α-(1,4)- and α-1,6)- are important in degradation process of 
glycogen to glucose. More branches causing more glucose released at once. The 
degradation process also known as a glycogenolysis process. This process occurs through 
the action of glycogen Phosphorylase. 
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2.2.1 Glycogen Phosphorylase Enzymes 
 
Glycogen phosphorylase is a phosphorylase enzyme that is important in the 
catalyzes or breakdown of glycogen in liver and tissue with high energy demands 
(David et al., 2005). This enzyme has been proposed in the treatment of diabetes type 2 
via the inhibition of released glucose in the liver (Martin et al., 1998; Ogawa et al., 
2003; Somsak et al., 2003; Treadway et al., 2001). The term phosphorylase is not 
derived from phosphorylation process, but from breaking a bond in glycogen. 
Glycogen phosphorylase form in 2 types which are phosphorylated phosphorylase b 
and phosphorylase a. The differences between these 2 enzymes are phosphorylase a 
form (Ser-PO42-) whereas b forms (Ser-OH).  The b form is less active and 
transformed to a form which is more active by phosphorylase kinase.  The glycogen 
phosphorylase a form is subsequently dephosphorylated by the action of protein 
phosphatases, it returned to less active b form (David et al., 2005). 
 
The breakdown or degradation of glycogen, known as glycogenolysis, remove 
single glucose residues from α-(1,4)-linkages and release glucose-1-phosphate (G1P) 
as a product reaction which then converted to glucose-6-phosphate (G6P) by 
phosphoglucomutase. G6P derived from glycogen is important in (1) continuing on the 
glycolysis pathway and use as energy for anaerobic or aerobic metabolism such as in 
muscle. (2) dephosphorylated back to glucose by glucose-6-phosphotase enzyme in 
gluconeogenesis pathway of liver and kidney and released into blood. (3) Produce 
NADPH and 5-carbon sugars in pentose phosphate pathway via glucose-6-phosphate 
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dehydrogenase enzyme (Berg et al., 2002). In muscle cells (myocytes), degradation of 
glycogen is important to provide source of glucose-6-phosphate for glycolysis which is 
important in supplying energy for muscle contraction. While in liver cells 
(hepatocytes), the breakdown of glycogen is important so that glucose can uptake by 
other cells. 
 
2.2.2 Glycogen Phosphorylase Inhibitor 
 
Glycogen Phosphorylase (GP) inhibitor have been developed and studied as 
potential therapy of hyperglycaemia (Moller, 2001; Somsak et al., 2003). 
Administration of GP inhibitor showed to reduce liver glycogen phosphorylase activity 
and attenuate hyperglycaemia without producing hypoglycaemia, a potential side effect 
by many antidiabetic agents (Martin et al., 1998; Ogawa et al., 2003).  Previous 
research also showed that GP inhibitor are effective in reducing hepatic glucose output 
in presence of higher glucose contents (Kasvinsky et al., 1978) and also cardio 
protective (Huang et al., 1988).  This situation important in protecting against rebound 
hypoglycaemia and reduce fatality cause by cardiovascular disease especially in type 2 
diabetes patients (Oikonomakos et al., 2000). The administration of glibenclamide in 
alloxan-induced diabetic rats was reported to have hypoglycaemic effects by increasing 
the insulin secretion, therefore stimulates the glycogen synthase and inhibit the 
glycogen phosphorylase activity (Gerich, 1989; Harrison, 2001; Nidhi et al., 2010). 
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2.3 Anti-hyperglyceamic Agents 
 
Management of diabetes mellitus consists of exercise, diet, and administration of 
common drug such as biguanides and sulfonylureas. These anti-hyperglyceamic drugs were 
categorized in different classes and were use depends on the type of diabetes, age, and 
condition of patients. Patients with diabetes type I required injections of insulin due to lack 
of insulin. It is because type 1 diabetes results from absolute deficiency of pancreatic β 
cells, thus most oral agents are not required. While for patients with diabetes type 2 
typically required oral agents due to insulin resistance (Fowler, 2007). There oral agents 
either works  (1) increased the amount of insulin secretion by pancreas (2) increase the 
sensitivity of target organ to insulin, or (3) decrease rate of glucose absorbance from 
gastrointestinal tract. Now a day, a lot of drugs are available. Metformin is the first drug 
prescribed in diabetes therapy. When metformin combined with diet and lifestyle 
intervention is not enough to reach the glycaemia target, other options are available such as 
sulfonylureas, pioglitazone, α glucosidase inhibitors and others (Derosa et al. 2012) 
 
2.3.1 Insulin 
 
Insulin is commonly used in the treatment of diabetes Type 1 as the lack of 
insulin produced is the cause of the disease. Insulin usually will be injected 
subcutaneously using syringe needles with insulin pump and also using repeated-use 
insulin pump with needles. In acute-care disease, insulin is given intravenously. It 
cannot be consume orally as it will be reduce to fragment in gastrointestinal tract and 
  
 
17 
 
lots their activity. Insulin is manufactured using DNA recombinant technology. 
Research by SembioSys Genetics company in 2007 has reported the successfully 
production of human insulin derived from seed of safflower as the global demand for 
the hormone grows (Levinson, 2007). This technique is believed to reduce the cost of 
insulin productions. The insulin is characterizes based on their metabolism rate; rapid 
acting insulin, intermediate acting insulin and long acting insulin. The rapid acting 
insulin have an effect as fast as 15 minutes due to mutation in sequence that prevent 
this type of insulin forming dimers and hexamer which can rapidly absorb. It is 
including Humulin R and Novolin R (Regular insulin), Humalog (lispro), Novolog 
(aspart), Apidra (glusine) and Semilente (insulin zinc). The intermediate acting insulin 
includes Humulin N and Novolin N, and Lente. While a long acting insulin includes 
Ultralente (extended insulin zinc), Lantus (glargine) and Levemir (detemir). These 
types of insulin have an effect that extended from 18 to 24 hours.  
 
2.3.2 Sensitizer 
 
Insulin sensitizers consist of two classes of drugs which are biguanide and 
thiazolidinedione. These types of drug are used in the treatment of diabetes type 2. 
Biguanides such as metformin (Glucophage) is commonly used for type 2 diabetes.  
Research reported that this drug is the best to consumed for patients who have heart 
failure (Eurich et al., 2007) with certain procedures. Metformin also showed to be safe 
and effective to gestational diabetes. Previous research reported that newborn babies 
with mother given metformin showed a healthier in neonatal period (Balani et al., 
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2009; Palshetkar et al., 2011; Tertti et al., 2008). Moreover, this drug also reported can 
prevents cardiovascular complications of diabetes via reducing LCL cholesterol and 
triglyceride level and at the same time is not causing weight gain (Bolen et al., 2007; 
Maharani, 2010). While phenformin (DBI) and buformin, was withdrawn due to lactic 
acidosis risk (Fimognari et al., 2006; Verdonck et al., 1981).  
Thiazolidinediones also known as glizones, is an anti-hyperglyceamic drug in the 
treatment of diabetes type 2. It acts in reducing insulin resistance by activating PPAR-y in 
fats and muscle. This type of drug consists of rosiglitazone (avandia), pioglitazone (actos) 
and Troglitazone (rezulin). Recent studies reported that rosiglitazone increase the risk of 
coronary heart disease and heart attacks (Home et al., 2009). In contrast, research on 
pioglitazone shows that this drug decrease the incidence of cardiac event in patient with 
diabetes type 2 with history of heart attack (Erdman et al., 2007). 
 
2.3.3 Secretagogues 
 
Insulin secretagogues are a substance that triggered the secretion of insulin. It is 
consists of sulfonylureas and meglitinides (non-sulfonylurea).  Both drugs used in the 
treatment of diabetes type 2 which they bind to the ATP-dependent K+ (KATP) channel 
on cell membrane of pancreatic beta cells. Thus, insulin is secreted. Sulfonylureas are 
safe to use as treatment of neonatal diabetes (Greeley et al., 2010; Oztekin et al., 
2012). Study had shows that this drug has no effect on blood pressure (Rodger, 1999). 
In high dose and patient is fasting, this drug can cause hypoglycaemia due to excesses 
in insulin release. Thus, it can lead to weight gain due to high glucose uptake. Glycated 
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haemoglobin (A1C) is use in second-generation of sulfonylureas. The high amount of 
glycated haemoglobin indicates poorer control in blood glucose level and associated 
with cardiovascular disease, nephropathy, and retinopathy. The reductions in 
haemoglobin by using second-generation of sulfonylureas are 1-2%. The second-
generation agent of sulfonylureas consists of glipizide, glibenclamide, gliclazide, 
glycopyramide and gliquidone. Meglitinide also known as Glinides and it has similar 
mechanism as sulfonylureas but have separate binding site. Contrast to sulfonylureas, 
this drug also can lead to weight gain and hypoglycaemia but the chance are lesser. 
Glycated haemoglobin (A1C) shows about 0.5-1% reduction during treatment with this 
drug. Meglitinides consists of repaglinide and nateglinide.  
 
2.3.4 Alpha-glucosidase Inhibitor 
 
The alpha-glucosidase inhibitor includes Arcabose, Miglitol and Voglibose. This 
drug used in the treatment of diabetes type 2. It is also is the best in treating impaired 
glucose tolerance at earliest stages. It is not a technically hypoglycaemic agent because this 
drug did not have direct effect on insulin secretion. This drug acts as preventing the 
digestion of carbohydrate such as starch and sugar (Bischoff, 1994). However, since the 
carbohydrate remain longer in the intestine, bacteria will digest this carbohydrate and 
causing gastrointestinal side effect such as flatulence (78% of patients) and diarrhoea (14% 
of patients) (Derosa et al., 2012). The alpha-glucosidase inhibitors also can found in natural 
products (Benalla et al., 2010; Ji et al., 2010). Research showed that this inhibitor also can 
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be found in plant such as mushroom maitake Grifola frondosa (Lo et al., 2008) and 
soybean (Lee et al., 2001).  
 
2.4 Medicinal Plants 
  
WHO currently encourage, facilitate, promotes and provide international standards 
guidelines in traditional medicine (Bodeker et al., 2000; World Health Organization, 2002). 
The WHO traditional medicine strategy program was introduced in early 2002 and the main 
objectives of this program are to discuss the role of this traditional medicine in healthcare 
system, challenges and their opportunities. Traditional medicine is widely used in Asia and 
Latin America due to their historical circumstances and cultural beliefs. For example in 
China, around 40% of health care used traditional medicine. In the developing country 
where the drugs are expensive and unaffordable by majority of diabetic patients, a wide 
range of medicinal plants have been used as an alternative therapy (Adesokan et al., 2009). 
At least 48% in Australia, 70% in Canada, 42% in USA, 38% in Belgium and 75% in 
France used this alternative treatment. In Malaysia, WHO (2005) estimated US$ 500 
million had spent on this treatment, and this showed that this treatment growing rapidly and 
become more popular. 
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Figure 2. 3 Percentages of populations in developed country 
(Source: WHO Traditional Medicine Strategy: 2002-2005) 
 
Medicinal plants have been known since ancient times in the treatment of the 
disease. Today, this treatment has been accepted as an important component of healthcare 
system. The worldwide has reported that the drug currently used in clinical practice have 
serious side effects. This situation makes people turn to medical plants as it is free from 
side effect, low cost and has significant effects (Pari et al., 1999). Other than the population 
rise, insufficient drugs supplies and development of resistance of infectious diseases to 
currently modern medicine, have led to the increasing of the usage of plant materials as an 
alternative treatments. 
 
There are 350,000 species of higher plants in the world and about 35,000 to 70,000 
of this species are used worldwide for traditional medicinal (Haidar et al., 2009; 
Lewington, 1990). This treatment is a traditional medicinal that are based on the use of 
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plants crude extract. There are a lot of scopes for this medicine, include bee product, 
minerals, fungal and certain animal parts (Acharya et al., 2008).  Asia countries likes 
Malaysia, China and India already consistently used this medicinal treatment especially 
among ethnic people. Meanwhile countries in Europe are beginning to explore these types 
of treatment. In Peninsular Malaysia, the unique values showed by the presence of three 
main races that are already having medicinal plant knowledge: the indigenous Malay 
medicinal knowledge, the Ayurvedic (Indian) school of medicine and the Oriental 
(Chinese) medicinal knowledge. This makes the field of medicinal plant are highly 
recommended and interesting. Estimated about 12,500 species existed in the forest and 
about 2000 species have been used in medicinal treatment in Malaysia (Bidin, 
1995).Previous study reported that approximately 2,000 species from 14,500 flowering 
plants have been reported to contains medicinal properties and many have been 
scientifically proven in Malaysia (Nardiah et al., 2010). The large scale of processing some 
of the important medicinal product has been started here. In 1999, about 1,546 of traditional 
medicine companied have been registered (Anonymous., 2009). In 1996, Malaysia 
Traditional & Complementary Medicine Unit was formed and registered. 
 
2.5 Hyperglyceamic Plants Compounds. 
 
According to WHO, approximately 80% of populations from the third countries are 
depends on medicinal plants as traditional therapies. Over 400 plants used in the treatment 
of diabetes mellitus in almost two thirds of the world population were observed (Musbah, 
1994; Singh  et al., 2011). The earliest study of hyperglyceamic plants was reported that 
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about 343 plants showed a potential in reducing blood glucose levels and has been 
classified (Atta-Ur-Rahman, 1989). Furthermore, Bailey and Day (1989) reported that 29 
isolated compounds were obtained and classified to 14 polysaccharides, 5 alkaloids, 4 
glycosides and 6 other compounds. Similarly, the earliest previous study also reported that 
there are four chemical groups of 78 different isolated compounds founds in hypoglycaemic 
plants (Ivorra et al., 1989), which are; 
i. Alkaloid (7 compounds) 
ii. Flavonoids and related compounds (5 compounds) 
iii. Terpenoid and steroids (7 compounds) 
iv. Polysaccharides and proteins (59 compounds) 
 
A single medicinal plant contain thousands of bioactive compounds, thus may have 
multiple effects in the treatment of diseases. The uses of medicinal plant, alone or in 
combination with other medicinal plants are believed can be a good combinations of 
therapy (Kaur et al., 2013). In hypoglycaemic plants, this combination may have multiple 
actions either in insulin action, insulin production or both (Chang et al., 2013). 
  
 
24 
 
 
Figure 2. 4 Mechanism actions of hypoglycaemic plants. The selected plants and compounds with their 
multiple anti-hyperglycaemic reactions; insulin resistance, β cell function, GLP1 or glucose reabsorption 
(Chang et al., 2013) 
 
 
A review study reported that the antidiabetic activities of bioactive compounds 
found in medicinal plants involved either in regulate insulin resistance, β cell function, 
GLP-1 homeostasis, glucose absorption in the gut, or with multiple antidiabetic actions 
(Chang et al., 2013). 
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Table 2. 1 Active compounds and biological actions of antidiabetic plants 
Antidiabetic 
Mechanism 
Plants Compounds Chemical Structure Reference 
 
Regulate insulin 
resistance 
 
G. uralensis 
Amorfrutin 1 
 
 
(Weidner et al., 
2012) 
Amorfrutin 2 
 
Amorfrutin 3 
 
Amorfrutin 4 
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Table 2.1 ‘Continued’ 
Antidiabetic 
Mechanism 
Plants Compounds Chemical Structure Reference 
 
Reduce 
insulin 
resistance 
 
G.elata 
 
Vanillin 
 
 
(Park et al., 
2011) 
4-
hydroxybenzaldehyde  
Regulate 
insulin 
resistance 
C.verum 
C.zeylanicum 
C.aromaticum 
Cinnamaldehyde 
 
(Liu et al., , 
2012) 
 
Reduce 
insulin 
resistance 
 
T. foenum-
graecum Diosgenin 
 
(Puri et al., 
2002; Uemura 
et al., 2010) 
Galactomannan 
 
(Puri et al., 
2002) 
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Table 2.1 ’Continued’ 
Antidiabetic 
Mechanism 
Plants Compounds Chemical Structure Reference 
 
Reduce insulin 
resistance 
 
T. foenum-
graecum 
Trigoneoside Xa 
 
 
(Puri et al., 2002) 
Trigoneside Xb 
 
Trigoneoside Xlb 
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Table 2.1 ‘Continued’ 
Antidiabetic 
Mechanism 
Plants Compounds Chemical Structure Reference 
 
Regulate β cell 
function 
C. papaya 
P. 
amaryllifolius 
Flavonoid, 
alkaloids, 
saponin, and 
tannins 
N.A 
(Sasidharan et al., 
2011) 
 
T. divaricate 
E. nicrophylla 
 
Conophyline 
 
(Kawakami et al., 
2010; Kodera et al., 
2009; Ogata et al., 
2004; Saito et al., 
2012) 
 
A.roxyburghii 
 
Kinsenoside 
 
(Zhang et al., 2007) 
 
N. stellata 
 
Nymphayol 
 
(Subash-Babu et al., 
2009) 
 
S. marianum 
 
Silybin 
 
(Jose et al., 2011; 
Soto et al., 2010; 
Vengerovskii et al., 
2007) 
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Table 2.1 ‘Continued’ 
Antidiabetic 
Mechanism 
Plants Compounds Chemical Structure Reference 
 
Regulate β cell 
function 
 
S. marianum 
 
Silydianin 
 
(Jose et al., 
2011; Soto et 
al., 2010; 
Vengerovskii et 
al., 2007) 
 
Silychristin 
 
 
B.pilosa 
3-𝛽-D-glucopyranosyl-1- 
hydroxy-6(E)-tetradecene- 
8,10,12-triyne 
 (Chien et al., 
2009; Ubillas et 
al., 2000) 
2-𝛽-D-glucopyranosyloxy-1- 
hydroxy-5(E)-tridecene-
7,9,11- 
triyne 
 
2-𝛽-D-glucopyranosyloxy-1- 
hydroxytrideca-5,7,9,11- 
tetrayne 
(cytopiloyne)  
(Liu et al., 
2012) 
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‘Table 2.1 ‘Continued’ 
Antidiabetic 
Mechanism 
Plants Compounds Chemical Structure Reference 
 
Regulate GIP-1 
homeostasis 
 
A.tequilana 
 
Inulin/Raftilose 
 
(Urlas-Silvas et al., 
2008) 
 
Olive oil 
 
 
Monounsaturated 
Fatty acids 
N.A 
(Gentilcore et al., 
2006) 
 
Regulate 
glucose 
absorption in 
guts 
 
C. tinctorius 
 
Serotonin 
derivatives 
 
(Takahashi et al., 
2012) 
 
L.japonica 
 
Butyl-isobutyl-
phthalate 
 
(Akar et al., 2011) 
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Table 2.1 Continued 
Antidiabetic 
Mechanism 
Plants Compounds Chemical Structure Reference 
 
Regulate two or 
more pathways  
 
B. vulgaris 
 
Berberine 
 
(Dong et al., 2012; 
Jeong et al., 2009) 
 
 
M. charantia 
 
Momordicin 
 
(Singh et al., 2011) 
  
Capsicum 
plants 
 
Capsaidin 
 
(Gram et al., 2007; 
Hwang et al., 2005) 
 
 
P. ginseng 
 
Ginsenoside Rb1 
Ginsenoside Rb2 
Ginsenoside Rc 
Ginsenoside Rd 
Ginsenoside Re 
Ginsenoside Rf 
Ginsenoside Rgf 
 
(Cho et al., 2006; 
Kao et al., 2007) 
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2.6 Studied Plant – Pereskia bleo 
 
Pereskia bleo (Kunth) DC tree is a species belongs to the botanical family 
Cactaceae (Tan et al., 2004).  It is commonly known as “jarum tujuh bilah” or “pohon 
jejarum” by Malaysian. It is also commonly known as leaf cactus, rose cactus and wax rose 
in English. While in Chinese, this plant known as cak sing cam.  
 
Kingdom: Plantae (Plants) 
Subkingdom: Viridaeplantae (Green plants) 
Division: Tracheophyta (Vascular plants) 
Subdivision: Spermatophytina (Seed plants) 
Class:  Magnoliopsida 
Order :  Caryophyllales 
Family: CactaceaeJuss (Cactus, cacti) 
Genus:  Pereskia Mill 
Species: P.bleo 
 
 
Pereskia bleo is originates from Paraguay, Argentina and Korea (Khor et al., 2013; 
Yusof, 2010). It has been cultivated in Malaysia for traditional medicine and also as 
decorative plant. This plant does not look much like other types of cacti, having substantial 
leaves and thin stems. They are the only cactus genus that has persistent non-succulent 
leaves. It is believed that this is the origin of other cacti. Most of the Pereskia species 
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correspond in dry forests or thorny scrub, in tropical climates with a dry season and very 
dry forest life except for Pereskia bleo which is lives in higher annual rainfall (Erika et al., 
2006).  
 
 
Figure 2. 5 Pereskia bleo (Kunth) DC; leaves, flower, fruit and stem. 
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This species may grow 2-8 meter high. Their leaves are large, bright green and 
privet-like leaves. They have long spiny stems and the young branches in red. It spines in 
fascicles of 5 or 6, but young shoots often bear but 1 to 4. These spines show development 
from areoles. The orange-red Flowers may appear alone or in clusters. They usually 
resemble roses and reach a diameter of 1 to 5 cm. Colours of the flower depends on the 
species and vary from white, yellow to magenta or red (Yusof, 2010). Fruits are ordinarily 
waxy spherical green with big and black colour. It will turn to yellow when ripe (Khor et 
al., 2013). 
 
2.6.1 Chemical Constituents 
 
Doetsch, (1998) has reported that the alkaloids isolation from Pereskia bleo were 
3,4-dimethroxy-β-phenethylamine, mescaline, 3-methoxytyramine and tyramine. Whereas, 
Goh (2000) reported that the isolated compounds presence in Pereskia bleo were stigma 
sterol, β-sitosterol, dihydroactinidiolide and campesterol. Ethyl acetate extract of Pereskia 
bleo was reported to contains β-sitosterol, 2,4-ditert-butylphenol, α-tocopherol and phytol 
(Sri Nurestri et al., 2008). 
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Table 2. 2 Chemical compounds reported found in Pereskia bleo. 
Chemical 
compounds 
Chemical Structure Reference 
Dihydroactinidiolide 
 
Appalaraju et al., 
2013; 
Goh, 2000 
Α-tocopherol 
 
Appalaraju et al., 
2013; 
Sri Nurestri et al., 
2008 
Phytol 
 
Sri Nurestri et al., 
2004 
Methyl palmitate 
 
Sri Nurestri et al., 
2009 
Methyl oleate 
 
Sri Nurestri et al., 
2009 
Methyl stearate 
 
Sri Nurestri et al., 
2009 
Phytol 
 
Sri Nurestri et al., 
2009; 
Sri Nurestri et al., 
2008 
Β-sitosterol 
 
 
 
Appalaraju et al., 
2013; 
Goh, 2000; 
Sri Nurestri et al., 
2008 
2,4-ditert-
butylphenol 
 
 
 
Appalaraju et al., 
2013, 
Sri Nurestri et al., 
2008 
Stigma sterol  
 
Appalaraju et al., 
2013; 
Goh, 2000 
Campesterol 
 
 
Appalaraju et al., 
2013; 
Goh, 2000 
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2.6.2 Medicinal Uses 
 
In Malaysia, the leaves of Pereskia bleo were used as a natural medicine and can be 
eaten as salad (Tan et al., 2004). Similarly, Pereskia grandifolia, one of medicinal plant 
under the same family with Pereskia bleo also has been traditionally used by local Malaysia 
as natural medicine in cancer-related disease, high blood pressure, diabetes, rheumatism, 
inflammation and ulcer (Goh, 2000; Sri-Nurestri et al., 2009). The leaves of this plant also 
used as traditional treatment for headache, gastric pain, haemorrhoids, atopic dermatitis, 
ulcers and also used to refresh the body (Goh, 2000; Rahmat, 2004; Tan et al., 2004). In 
previous cytotoxic study, this plant has been reported to have cytotoxic effects on various 
cancer cell lines but not in normal cell lines. (Sim et al., 2010). Furthermore, previous study 
of acute oral toxicity on experimental ICR mice also showed that there are no mortality 
occurred when ICR mice were induced with both Pereskia bleo and Pereskia grandifolia 
(Sim et al., 2010). Current drugs used in the treatment of diabetes are always associated 
with several side effects. Therefore, oral hyperglyceamic agents that are safe, and effective 
are needed (Murthy, 1995; Nidhi et al., 2010). Pereskia bleo also reported commonly used 
as antidiabetic and hypertension treatment for certain ethnic in Malaysia (Tan et al., 2004). 
However, there are no scientific reports indicates that this plant contained anti-diabetic 
effects (Khor et a l., 2013).  
 
 
 
 
  
 
37 
 
2.7 Research Objectives 
 
The main objectives of the study are: 
1. To investigate the profile of organic compounds from Pereskia  
2. To assay the glycogen phosphorylase inhibitory activity of the plant crude 
extracts and isolated compounds 
3. To evaluate the effect of Pereskia bleo aqueous crude extracts as antidiabetic 
agents in Sprague Dawley (SD) rats 
4.  To evaluate the toxicity of Pereskia bleo using Brine Shrimp Lethality Assay 
(BSLA) 
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3.1 Experimental Materials 
 
 
Figure 3. 1 Samples of Pereskia bleo (Jarum Tujuh Bilah) 
 
Samples of leaves, stems and roots of Pereskia bleo were collected at Rimba Ilmu, 
University Malaya. It taxonomic identification was verified by Prof Ong Hean Chooi from 
Institute Science Biology, Faculty of Science, University Malaya. Mice were purchased 
from Animal House, University Malaya. Sprague Dawley (SD) rats were purchased from 
Bumi Kenyalang Sdn. Bhd. Glipizide and glycogen was purchased from Fisher Scientific 
(M) Sdn. Bhd. All chemical and reagents were analytical grade and purchased from Fisher 
Scientific (M) Sdn. Bhd. Silica gel 60 F254 plates (20x20 cm, 0.5mm thickness) were 
purchased from Merck Sdn. Bhd. Silica gel 60 (0.063-0.200mm) for column 
Chromatography were purchased from Megalab Supplies.  
 
  
 
39 
 
3.2 Extraction of Plant Chemical Compounds 
 
Samples of leaves, stem and roots were clean and dried into constant weight in oven 
at 40oC and ground to become powder form. These dried powder of each samples were 
exhaustively extracted in ratio 1:10 with four different solvents which are hexane, 
petroleum ether, chloroform, and methanol. Extractions were done separately using soxhlet 
apparatus started with hexane and followed by more polar solvents. Extraction for each 
samples were done for 72 hours at 30oC to ensure that all active compounds were 
completely extracted out. After 72 hours, the crude extracts were filtered with Whatman 
Filter Paper Grade 1. Aqueous extraction was done by using conventional method. Samples 
were soaked with distilled water and were place in aqueous bath at room temperature for 3 
hours. All these samples were evaporated into concentrated volume using a rotary 
evaporator at 40oC. These concentrated crude extract were then placed in a freeze drier and 
were left to run under pressure. The dried extracts were collected and stored at -20oC for 
further test. 
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Figure 3. 2 Soxhlet Apparatus 
 
 
3.3 Separation And Detection Of Chemical Compounds 
3.3.1 Thin Layer Chromatography (TLC) 
 
Samples are prepared in 0.01gml-1. Heparins capillaries were used to spot 
sample on TLC plate. The samples were spotted in one line about 1cm for couple of 
times to ensure it is visible.  
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2cm 
9cm 
1cm 
1cm 
Sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 3 Illustration of sample’s draw on TLC plates. 
 
TLC separation was carried out on silica gel 60 F254 plates (20x20 cm, 0.5mm 
thickness) with a combination of Toluene:ethyl acetate (30:70, v/v), Toluene:ethyl 
acetate (7:93, v/v) and Methanol:chloroform (1:9, v/v) as a mobile phase. But only 
Toluene:ethyl acetate (30:70, v/v) was selected as a mobile phase for further test. The 
reason was explained in chapter 5. Development glass jar was filled with small amount 
of mobile phase approximately less than 1 cm in depth. Development glass jar was 
then covered with watch glass to create an atmosphere saturated with mobile phase. 
TLC plates that were drawn with a line of sample were placed in the development glass 
jar and were left for a few minutes until the solvents risen up on top of the TLC plate 
(Figure 3.4). After the solvent risen up on top of the TLC plate, TLC plate was 
removed and a front line was drawn across the plate. These front lines are important 
for Rf calculations. TLC plates were observed for any coloured band presence with 
visible light and under UV light. Detection of compounds presence was further tested 
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using chemical reagents. Difference chemical reagents were used to detect difference 
chemical compounds.  
 
 
 
Figure 3. 4 TLC plates were placed in the development glass jar. 
 
Two spray reagents were used were Dragendorff reagent and Vanillin-sulphuric 
acid reagent. Dragendorff reagent was used in the detection of alkaloid compound. 
This reagent was prepared by adding 1.7 g basic bismuth nitrate with 20 g tartaric acid 
and 80ml distilled water for solution A. While in solution B, 16g potassium iodide was 
added with 40ml distilled water. Both solutions were then mixed together in ratio 1:1 
as a stock solution.  
 
The vanillin-sulphuric acid reagent was used in the detection of terpenoid 
compound. This reagent was prepared by mixing 0.5g vanillin powder with 100ml 
sulphuric acid. After sprayed with vanillin reagent, the TLC plates were then heated at 
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120oC until maximum colour appeared. After sprayed with both reagents, TLC plates 
were observed under visible and UV light for any coloured band arises.  
 
3.3.2 Column Chromatography (CC) 
 
Hexane, petroleum ether, chloroforms and methanol crude extracts of stem, root 
and leaves of Pereskia bleo were prepared in 0.01g/ml. This concentration was used as 
a standard concentration of samples in further test. Silica gel was used as a stationary 
phase and combinations of Toluene-ethyl acetate (30:70, v/v) as a mobile phase. While 
for aqueous crude extract of leaves, stems and roots of Pereskia bleo, column 
chromatography was developed using combination of butane, acetic acid and distilled 
water at ratio 60:15:25 as mobile phases. The mixed of silica gel and solvents yield a 
thick white slurry. A plug of glass wool was placed at the end of burette as prevention 
from any contamination of fractions collected from silica gel. Then 18 ml mixture of 
silica gel and solvents was loaded into burette slowly to avoid any air bubble. 0.5 ml of 
prepared samples was loaded at top of packed column. Samples were eluted in column 
at flow rate of 1ml per minutes. Ten fractions were collected with 5 ml each. These 
fractions were left dried in fume hood before stored at -20oC for further test according 
to Harbone (1973) with slightly modifications.  
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3.3.3 Liquid Chromatography Mass Spectrometry (LCMS/MS) 
 
An AB Sciex 3200QTrap mass spectrometer (AB Sciex California, USA) was 
used to determine the bioactive compound of Pereskia bleo with column Phenomenex 
aqua C18-50mm x 2.0mm x 5µM. All data were analyzed using electrospray ionization 
(ESI) source in negative ion mode with settings; capillary voltage of ESI-MS -4500kV 
and temperature 500oC, collision energy spread at 35eV +/- 15eV, purified Nitrogen 
gas (N2) 99.9995% as nebulisation and desolvation gas (Gas 1 40 psi, Gas 2 40 psi), 
declustering potential -40V. Full scan data acquisitions were performed for 
identification of unknown compounds at m/z range 100-1200 in profile mode. MS/MS 
experiments (product ion scan) were performed to confirm the identity of bioactive 
compounds presence in plant crude extracts.  The buffer A contained distilled water 
with 0.1% formic acid and 5mM ammonium formate, while buffer B contained 
Acetonitrile with 0.1% formic acid and 5mM ammonium formate. The gradient was 
run in 10% A and increased to 90% B from duration 0.01 minutes to 8.0 minutes. After 
3 minutes, gradient was switched back to 10% A in 0.1 minutes. Column was 
equilibrated for 5 minutes before next injection. All data were obtained and processed 
using AB Sciex Analyst 1.5 software. 
 
3.4 Determinations Of Total Phenolics Contents 
 
The total phenolics contents were determined by Follin-Ciocalteau method with 
slightly modification (Amin et al., 2006). 10mg/ml of standard concentration samples in 
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methanol (1:1) were mixed with 5.0 ml Follin-Ciocalteau reagent (1:10 diluted with 
distilled water) and 4.0ml 1M Na2CO3. The mixtures were then incubated at 450
oC for 15 
minutes. Absorbance was measured at 765nm using spectrophotometer. Total phenolics 
was determined using a standard curve with gallic acid (0-125mg/ml) and was expressed in 
mg of gallic acid equivalents (GAE) per gram of dry sample. 
 
3.5 Determinations Of Total Flavonoids Contents 
 
Flavonoids contents were determined using aluminium chloride colorimetric 
method with slightly modification (Liu et al., 2007). 10mg/ml of standard concentration 
samples in methanol (1:1) were mixed with 0.3ml 5% NaNO2 and incubated for 5 minutes 
at 370oC. 0.3ml 10% AlCl3 was added and incubated 6 minutes at 370
oC. 2.0ml NaOH and 
10ml distilled water were added and absorbance was measured at 510nm using 
spectrophotometer using methanol as a blank. Total flavonoids were determined using a 
standard curve of quarcetin (0-2.5mg/ml). Total flavonoids content was expressed as mg of 
quarcetin equivalent (QUE) per gram of dry sample. 
 
3.6 Brine Shrimp Lethality Bioassay (BSLA) 
 
The cytotoxic activity of Pereskia bleo extracts were measured using Brine shrimp 
lethality bioassay according to Meyer (1982) with slightly modifications. The artificial sea 
water was prepared by dissolving 38g sea salt into 1 litre of distilled water. This sea water 
was loaded in small tank and divided into 2 sides. One of these sides was loaded with half 
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of spoon shrimp eggs and covered with aluminium foil. After 2 days, the shrimps were 
hatched and matured as Brine shrimp nauplii. The lamp was placed to another side, to 
attract Brine shrimp nauplii to go through the aluminium foil hole. The 100 µg/ml 
concentration of samples stocks were prepared by adding Pereskia bleo samples with 
dimethyl sulfoxide (DMSO) solutions and diluted with artificial sea water. Serial dilutions 
of samples at concentration 10, 100 and 1000 µg/ml were prepared from these stocks. 
Samples and ten live nauplii were placed in each of vials. After 24 hours, nauplii in each 
vial were observed using magnifying glass and the number of survived nauplii were 
counted and recorded. The lethal concentrations (LC50) were determined at 95% 
confidence intervals by analyzing the data on Finney Programmer (Olaleye, 2007). The 
bioassay was done in triplicate. 
 
3.7 Antidiabetic 
3.7.1 Glycogen Phosphorylase Inhibitor Bioassay (GP) 
 
The enzymatic inhibition of phosphorylase activity was monitored using 
microplate reader (Bio-Rad) following the methods as described by Martin, (1998) 
with slight modification. GPa activity was measured in the direction of glycogen 
synthesis by the release of phosphate from glucose-1-phosphate. Each compound was 
dissolved in DMSO and diluted at five different concentrations for IC50 determination. 
The enzymes were added into the 1L buffer with compounds dissolved in a mixture of 
50 mM Hepes (pH 7.2), 100 mM KCl, 2.5 mM MgCl2, 0.5 mM glucose-1-phosphate, 
and 1 mg/mL glycogen in 96-well microplates (Costar). Then, lL of 1 M HCl 
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containing 10 mg/mL ammonium molybdate and 0.38 mg/mL malachite green were 
added to the mixture. Reactions were run at 22oC for 25s min. The phosphate 
absorbance was measured at 655 nm. The IC50 values were estimated by fitting the 
inhibition data to a dose-dependent curve using a logistic derivative equation. 
 
3.7.2 Treatments on Sprague Dawley (SD) Rats 
3.7.2.1 Experimental Animals 
 
Both healthy male and female Sprague-Dawley (SD) rats ages between 12 to 15 
weeks and weight between 100 to 150g was supplied from Animal House University 
Malaya, Kuala Lumpur. SD rats were used after acclimatized for 7 days and were 
housed individually in separate cages under standard conditions which were 12 hours 
light and 12 hours dark, under room temperature. SD rats were provided with standard 
pellets diet that were also supplied by Animal house, University Malaya and given 
water ad libitium. Animal study was approved by Animal House, University Malaya 
with Animal Care and Use Committee (ACUC) with ethic number 
ISB/05/05/2010/NAMD (R). 
 
3.7.2.2 Acute Toxicity Study 
 
The acute toxicity test was carried out according to Barik, (2008) with slightly 
modifications. Both healthy male and female Sprague Dawley rats were fasted 
overnight and divided into 7 groups, with 6 rats in each group. These rats were 
administrated with Pereskia bleo aqueous extract in increased dose levels from 250, 
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500 and 1000 mg/kg body weight by oral gavages. SD rats were observed continuously 
for 2 hours, 24 hours, 72 hours and 7 days under the following profiles:  
 
 
i. Behavioral; fearfulness, irritability 
ii. Autonomic profile; Urination, defecation. 
iii. Neurological profile; Pain response, spontaneous activities.  
iv. Mortality 
 
3.7.2.3 Oral Glucose Tolerance Test (OGTT)  
 
OGTT was performed based on Shiwaikar, (2006) with slightly modifications. 
The healthy rats’ averages weights between 150 to 200g were fasted overnight for 8 to 
12 hours before the test started. Eight groups contained of six SD rats were divided 
according to the samples and doses below (Table 3.1). A dose of Pereskia bleo extracts 
was prepared at 250mg/kg and 500mg/kg body weight. Each group was administrated 
with saline 0.9% and Pereskia bleo extracts. A standard dose of glucose was prepared 
at 3g/kg body weight and administrated by oral gavages to all SD rats after 30 minutes. 
Small amount of blood samples taken from the tail at 0, 30, 60, 90 and 120 minutes 
were used for blood glucose level (mg/dL) measurement using glucometer (Accu-
Check PERFOMA). The results were recorded and the curves obtained from graph 
were observed to determine the responds of rats to glucose assumptions.  
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Table 3. 1 Groups were divided into each samples and dosage. 
Groups 
(n=6) 
Samples Dose 
I Control (saline 0.9%) - 
II 
Standard reference 
(Glipizide) 
3mg/kg 
III Leaf aqueous extract 250mg/kg 
IV Leaf aqueous extract 500mg/kg 
V Stem aqueous extract 250mg/kg 
VI Stem aqueous extract 500mg/kg 
VII Roots aqueous extract 250mg/kg 
VIII Roots aqueous extract 500mg/kg 
 
3.7.2.4 Induction of non-insulin dependent diabetes mellitus (NIDDM) 
 
Both male and female SD rats were induced to become diabetic using previous 
methods with slightly modifications (Mukhtar et al., 2004). Both healthy male and 
female SD rats weight between 100 to 150g were fasted overnight and induced by a 
single intraperitoneal injection of 120mgkg-1 body weight of alloxan monohydrate. 
After 72 hours, the rise of blood glucose level which was more than 150mg/dl were 
considered as diabetic. SD rats with permanent NIDDM for 7 days were used for the 
anti-diabetic study. 
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3.7.2.5 Anti-diabetic effect of Pereskia bleo aqueous extracts. 
 
SD rats were divided into nine groups, consisting of six rats per group. Glipizide 
was used as standard drug. The extracts and standard drug were administrated for 25 days 
to each group as below; 
 
Group 1: Non diabetic rats administrated with saline. 
Group 2: Diabetic rats administrated with saline. 
Group 3: Diabetic rats administrated with Glipizide 3 mg/kg. 
Group 4: Diabetic rats administrated with leaves aqueous extract 250mg/kg. 
Group 5: Diabetic rats administrated with leaves aqueous extract 500mg/kg. 
Group 6: Diabetic rats administrated with stem aqueous extract 250mg/kg 
Group 7: Diabetic rats administrated with stem aqueous extract 500mg/kg. 
Group 8: Diabetic rats administrated with root aqueous extract 250mg/kg. 
Group 9: Diabetic rats administrated with root aqueous extract 500mg/kg. 
 
The effects of Pereskia bleo extracts in diabetic rats were observed and 
compared with a group given with standard drug (Glipizide). Fasting blood glucose 
was estimated on days 0, 5, 10, 15, 20 and day 25. Their blood glucose levels were 
measured using Glucometer (Accu-Check PEFORMA).  
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3.7.2.6 Biochemical Parameters 
 
On day 25, SD rats were sacrificed by cervical dislocation after overnight 
fasting. Bloods were collected and stored in EDTA blood tubes to further test for their 
lipid profiles, liver function tests, and renal function tests that were measured in a 
Biohealth Science laboratory, Institute of Biological Sciences, Faculty of Science, 
University of Malaya. 
 
3.7.2.7 Statistical Analysis 
 
 
All data were collected and statistically evaluated using one-way ANOVA, 
followed by Dunnett test using the SPSS software, version 2.0. The values p<0.05 were 
considered significant. 
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4.1 Extractions of Plant Chemical Compounds. 
 
 
Hexane, petroleum ether, chloroform and methanol extract were obtained using a 
Soxhlet apparatus as described in the methodology. While aqueous extract was obtained by 
soaking with distilled water and incubated in a water bath at 40-50oC for 3 hours. These 
extracts were then evaporated under pressure and stored in -20oC for further tests. The 
extracts from different parts of Pereskia bleo gave different colours and percentages of 
yield were summarized in Table 4.1. 
 
Table 4.1 Samples of Pereskia bleo crude extracts at five different solvent systems. 
. 
Samples 
 
Colours  / Yield (%) 
Hexane 
Petroleum 
Ether 
Chloroform Methanol Aqueous 
Leaves 
Dark green++ 
3.32g 
Light green+++ 
2.08g 
Dark green+++ 
2.11g 
Light green+++ 
2.49g 
Dark green+++ 
8.4g 
Stem 
Light green++ 
2.1g 
Light green+ 
1.7g 
Light green++ 
1.83g 
Light green+ 
2.51g 
Brown++ 
7,15g 
Root 
Colourless 
1.32g 
Colourless 
1.08g 
Colourless 
1.21g 
Light green+ 
2.39g 
Brown+++ 
3.63g 
 
Indications of intensity of colour:  +++ Strong  ++ Medium + Weak 
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4.2 Separation and Detections of Chemical Compounds 
4.2.1 Thin Layer Chromatography (TLC) of Leaves Pereskia bleo  
 
Based on Table 4.2, 6 compounds were detected in leaves Pereskia bleo hexane 
crude extract. These compounds were identified as alkaloid, phenol and terpenoid 
according to the colour appeared after sprayed with vanillin-sulphuric acid and dragendorff 
reagents. However, 7 compounds could not be detected by chemical reagents and were 
classified as unknown. 
 
19 compounds were detected in leaves Pereskia bleo petroleum ether crude extract. 
These compounds were identified as alkaloid, flavonoids and terpenoid according to the 
colour appeared after TLC plates were sprayed with vanillin-sulphuric acid and dragendorff 
reagents. Five unknown compounds were detected (Table 4.3). 
 
In Thin Layer Chromatography (TLC) of leaves Pereskia bleo chloroform crude 
extract, 12 compounds were detected as alkaloid, phenol, flavonoids and terpenoid based 
on the colour appeared after sprayed with vanillin-sulphuric acid and dragendorff reagents. 
While five unknown compounds were detected (Table 4.4). 
 
Table 4.5 showed the Thin Layer Chromatography (TLC) analysis of leaves 
Pereskia bleo methanol crude extract. 14 compounds were detected and revealed as phenol, 
flavonoids and terpenoid according to the colour appeared after sprayed with vanillin-
sulphuric acid and dragendorff reagents. While one compound was detected as unknown 
compound due to could not be detected by reagents. 
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Table 4.2 TLC analysis of leaves Pereskia bleo hexane crude extract. 
 
Labels Rf Colour  Reagents Comment 
Compounds Value 
Visible 
light 
UV light 
 
Dragendorff 
Vanillin-
H2SO4 
 
LH 1 0.986 O +++ -  O+++ - Alkaloid 
LH 2 0.950 D.G+++ -  D.G+++ D.G++ Unknown 
LH 3 0.907 L.G++ -  L.G+ Pr++ Terpenoid 
LH 4 0.879 D.G+ -  L.G+ Pr ++ Terpenoid 
LH 5 0.836 Y+ -  ++ Pr ++ Terpenoid 
LH 6 0.800 Y++ -  Y+ - Alkaloid 
LH 7 0.750 O ++ -  O+ - Alkaloid 
LH 8 0.743 O ++ -  - Pr+++ Terpenoid 
LH 9 0.707 L.G++ -  L.G+ Pk+ Phenol 
LH 10 0.693 L.G++ -  L.G+ - Unknown 
LH 11 0.629 - -  - Pr +++ Terpenoid 
LH 12 0.586 L.G++ -  L.G+ Pk+ Phenol 
LH 13 0.543 L.G++ -  L.G+ - Unknown 
LH 14 0.514 O + -  L.G+ - Unknown 
LH 15 0.493 L.G+ -  L.G+ - Unknown 
LH 16 0.464 O + -  - - Unknown 
LH 17 0.386 O +++ -  O+++ - Alkaloid 
LH 18 0.371 O +++ -  - Pr ++ Terpenoid 
LH 19 0.329 O ++ -  O++ - Alkaloid 
LH 20 0.271 O++ -  O++ - Alkaloid 
LH 21 0.207 L.G+ -  L.G+ - Unknown 
 
Indications:  +++ Strong  ++ Medium + Weak 
Colour: 
- No colour   Pr Purple 
O Orange   Pk Pink 
L.G Light green  L.B Light blue 
D.G Dark green  D.B D.Blue 
Y Yellow   D.BF Dark Blue Fluorescent 
OF Orange Fluorescent            PrF Purple Fluorescent 
RF Red Fluorescent 
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Table 4. 3 TLC analysis of leaves Pereskia bleo petroleum ether crude extract. 
 
Label Rf Colour  Reagents Comment 
Compound Value Visible light UV light 
 
Dragendorff 
Vanillin-
H2SO4 
 
LP 1 1.000 O+++ -  - Pr +++ Terpenoid 
LP 2 0.986 O+++ -  O+++ - Alkaloid 
LP 3 0.900 D.G+++ -  D.G+++ D.G+++ Unknown 
LP 4 0.836 Y+ -  Y++ L.G++ Alkaloid 
LP 5 0.871 - -  - Pr++ Terpenoid 
LP 6 0.814 D.G+ -  L.G+ L.G++ Unknown 
LP 7 0.714 Y+ -  - Pr+ Terpenoid 
LP 8 0.657 O+ -  O+ Pr++ 
Terpenoid/ 
Alkaloid 
LP 9 0.600 O+ OF++  O+ - 
Alkaloid/ 
Flavonoids 
LP 10 0.571 L.G+ -  - Pr+++ Terpenoid 
LP 11 0.500 L.G++ -  Y+ - Unknown 
LP 12 0.471 - -  - Pr++ Terpenoid 
LP 13 0.414 O+ -  - Pr+++ Terpenoid 
LP 14 0.329 L.G+ -  - - Unknown 
LP 15 0.257 O+++ -  O+++ - Alkaloid 
LP 16 0.229 Y+ -  O+ - Alkaloid 
LP 17 0.200 Y+ -  - Pr+ Terpenoid 
LP 18 0.143 - -  L.G++ - Unknown 
LP 19 0.129 - -  - Pr++ Terpenoid 
 
Indications:  +++ Strong  ++ Medium + Weak 
Colour: 
- No colour   Pr Purple 
O Orange   Pk Pink 
L.G Light green  L.B Light blue 
D.G Dark green  D.B D.Blue  
Y Yellow              D.BF Dark Blue Fluorescent 
OF Orange Fluorescent            PrF Purple Fluorescent 
RF Red Fluorescent 
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Table 4. 4  TLC analysis of leaves Pereskia bleo chloroform crude extract. 
 
Label Rf Colour  Reagents Comment 
Compound Value 
Visible 
light 
UV light  Dragendorff 
Vanillin-
H2SO4 
 
LC 1 0.920 D.G+++ -  D.G+++ Pk++ Phenol 
LC 2 0.840 L.G+++ OF++  O+ - 
Alkaloid/ 
Flavonoids 
LC 3 0.800 D.G++ -  D.G+ - Unknown 
LC 4 0.740 L.G++ OF++  L.G+ Pk+ 
Phenol/ 
Flavonoids 
LC 5 0.670 D.G+++ -  D.G+++ - Unknown 
LC 6 0.640 D.G+++ -  O++ - Alkaloid 
LC 7 0.570 L.G+++ OF++  D.G+ Pk+ 
Phenol/ 
Flavonoids 
LC 8 0.510 D.G++ -  - Pk+ Phenol 
LC 9 0.450 L.G++ -  - - Unknown 
LC 10 0.340 L.G++ -  - - Unknown 
LC 11 0.260 L.G++ -  - - Unknown 
LC 12 0.190 L.G++ -  - Pr++ Terpenoid 
 
Indications:  +++ Strong  ++ Medium + Weak 
Colour: 
- No colour   Pr Purple 
O Orange   Pk Pink 
L.G Light green  L.B Light blue 
D.G Dark green  D.B D.Blue  
Y Yellow              D.BF Dark Blue Fluorescent 
OF Orange Fluorescent            PrF Purple Fluorescent 
RF Red Fluorescent 
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Table 4. 5 TLC analysis of leaves of Pereskia bleo methanol crude extract. 
 
Labelled Rf Colour  Reagents Comment 
Compound Value 
Visible 
light 
UV light  Dragendorff 
Vanillin-
H2SO4 
 
LM 1 1.000 - -  - Pr+ Terpenoid 
LM 2 0.886 D.G++ -  D.G++ Pk++ Phenol 
LM 3 0.800 L.G++ -  L.G+ - Unknown 
LM 4 0.707 D.G+ -  L.G+ Pk++ Phenol 
LM 5 0.643 L.G+ OF++  L.G+ - Flavonoids 
LM 6 0.607 L.G+ -  L.G+ Pr ++ Terpenoid 
LM 7 0.586 L.G+ -  L.G+ Pk + Phenol 
LM 8 0.500 - -  - Pr + Terpenoid 
LM 9 0.470 L.G+ -  L.G+ Pk + Phenol 
LM 10 0.386 L.G+ -  L.G+ Pr + Terpenoid 
LM 11 0.371 L.G+ -  L.G+ Pk + Phenol 
LM 12 0.314 - -  - P +++ Terpenoid 
LM 13 0.271 L.G+ -  L.G+ Pk + Phenol 
LM 14 0.243 L.G+ -  L.G+ Pk + Phenol 
 
Indications:  +++ Strong  ++ Medium + Weak 
Colour: 
- No colour   Pr Purple 
O Orange   Pk Pink 
L.G Light green  L.B Light blue 
D.G Dark green  D.B D.Blue  
Y Yellow              D.BF Dark Blue Fluorescent 
OF Orange Fluorescent            PrF Purple Fluorescent 
RF Red Fluorescent 
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4.2.2 Thin Layer Chromatography (TLC) of Stems Pereskia bleo 
 
Table 4.6 showed the Thin Layer Chromatography (TLC) analysis has revealed the 
presence of 13 compounds identified as alkaloid, phenol, flavonoids and terpenoid while 1 
unknown compound detected in stem Pereskia bleo hexane crude extract.  
 
In stem Pereskia bleo petroleum ether crude extract, 9 compounds were revealed in 
Thin Layer Chromatography (TLC). These compounds were identified as terpenoid, 
flavonoids and alkaloid according to colour appeared after sprayed with vanillin-sulphuric 
acid and dragendorff reagents. While three compounds were identified as unknown 
compound (Table 4.7). 
 
In stem Pereskia bleo chloroform crude extract, 14 compounds were revealed in 
Thin Layer Chromatography (TLC). These compounds were identified as alkaloid, phenol 
and terpenoid according to colour appeared after sprayed with vanillin-sulphuric acid and 
dragendorff reagents. No unknown compound was detected (Table 4.8). 
 
While in stem Pereskia bleo methanol crude extract, 6 compounds were revealed in 
Thin Layer Chromatography (TLC). These compounds were identified as terpenoid and 
phenol according to colour appeared after sprayed with vanillin-sulphuric acid and 
dragendorff reagents. No unknown compound was detected (Table 4.9). 
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Table 4. 6 TLC analysis of stem Pereskia bleo hexane crude extract. 
Labelled Rf Colour  Reagents Comment 
Compound Value 
Visible 
light 
UV light  Dragendorff 
Vanillin-
H2SO4 
 
SH 1 0.97 Y+ OF+++  - Pr+++ 
Terpenoid 
Flavonoids 
SH 2 0.964 Y+ OF+++  O++ - 
Alkaloid 
Flavonoids 
SH 3 0.905 D.G+++ -  - Pk +++ Phenol 
SH  4 0.846 L.G++ OF+++  - Pk ++ 
Phenol 
Flavonoids 
SH 5 0.78 Y++ -  - Pr++ Terpenoid 
SH 6 0.677 - Y+  - Pr +++ Terpenoid 
SH 7 0.596 - Pk+  - R++ Phenol 
SH 8 0.537 - Y+  L.G+ Pr ++ Terpenoid 
SH 9 0.368 Y+++ -  - Pr +++ Terpenoid 
SH 10 0.304 - -  - - Unknown 
SH 11 0.177 L.G++ Y+++  - Pr ++ Terpenoid 
SH 12 0.118 O+++ OF++  - Pk+ 
Phenol 
Flavonoids 
SH 13 0.063 D.G++ Pk++  - Pr+ Terpenoid 
 
Indications:  +++ Strong  ++ Medium + Weak 
Colour: 
- No colour   Pr Purple 
O Orange   Pk Pink 
L.G Light green  L.B Light blue 
D.G Dark green  D.B D.Blue  
Y Yellow              D.BF Dark Blue Fluorescent 
OF Orange Fluorescent            PrF Purple Fluorescent 
RF Red Fluorescent 
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Table 4. 7 TLC analysis of stem Pereskia bleo petroleum ether crude extract. 
 
Labelled Rf Colour  Reagents Comment 
Compound Value 
Visible 
light 
UV light 
 
Dragendorff 
Vanillin-
H2SO4 
 
SP 1 1.000 - -  - Pr +++ Terpenoid 
SP 2 0.985 Y++ -  - - Unknown 
SP 3 0.933 D.G++ -  - - Unknown 
SP 4 0.88 D.G ++ OF++  - - Flavonoids 
SP 5 0.603 Y++ OF+  - - Flavonoids 
SP 6 0.682 - -  - Pr+++ Terpenoid 
SP 7 0.545 - -  - Pr ++ Terpenoid 
SP 8 0.230 O+++ -  O+++ - 
Alkaloid 
Flavonoids 
SP 9 0.097 L.G++ Y+  - - Unknown 
 
Indications:  +++ Strong  ++ Medium + Weak 
Colour: 
- No colour   Pr Purple 
O Orange   Pk Pink 
L.G Light green  L.B Light blue 
D.G Dark green  D.B D.Blue  
Y Yellow              D.BF Dark Blue Fluorescent 
OF Orange Fluorescent            PrF Purple Fluorescent 
RF Red Fluorescent 
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Table 4. 8 TLC analysis of stem Pereskia bleo chloroform crude extract. 
 
Labelled Rf Colour  Reagents Comment 
Compound Value 
Visible 
light 
UV light  Dragendorff 
Vanillin-
H2SO4 
 
SC 1 0.986 Y+ -  Y+ Pr+++ Terpenoid 
SC 2 0.879 D.G+++ D.BF+++  D.G++ Pk+++ Phenol 
SC 3 0.815 L.G+++ D.BF++  L.G+++ Pk+++ Phenol 
SC 4 0.729 L.G+ -  O+ - Alkaloid 
SC 5 0.272 Y+++ -  L.G+ Pr + Terpenoid 
SC 6 0.086 O+++ -  O+++ Y+++ Alkaloid 
SC 7 0.043 D.G+++ PrF+++  D.G+++ Pk+++ Phenol 
SC 8 0.029 L.G+++ -  D.G++ Pk+++ Phenol 
SC 9 0.586 - D.BF++  - O++ Phenol 
SC 10 0.643 - D.BF++  Y+ Pr +++ 
Terpenoid 
Phenol 
SC 11 0.513 - -  - Pr +++ Terpenoid 
SC 12 0.443 - -  - Pr+++ Terpenoid 
SC 13 0.229 - -  - Pr+++ Terpenoid 
SC 14 0.186 - -  - Pr++ Terpenoid 
 
Indications:  +++ Strong  ++ Medium + Weak 
Colour: 
- No colour   Pr Purple 
O Orange   Pk Pink 
L.G Light green  L.B Light blue 
D.G Dark green  D.B D.Blue  
Y Yellow              D.BF Dark Blue Fluorescent 
OF Orange Fluorescent            PrF Purple Fluorescent 
RF Red Fluorescent 
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Table 4. 9 TLC analysis of stem Pereskia bleo methanol crude extract. 
 
Labelled Rf Colour  Reagents Comment 
Compound Value 
Visible 
light 
UV light 
 
Dragendorff 
Vanillin-
H2SO4 
 
SM 1 0.956 - -  - Pr +++ Terpenoid 
SM 2 0.926 - D.BF+  - - Phenol 
SM 3 0.853 - -  - Pr++ Terpenoid 
SM 4 0.676 - -  - Pr+ Terpenoid 
SM 5 0.485 - -  - Pr +++ Terpenoid 
SM 6 0.441 - D.BF+  - - Phenol 
 
Indications:  +++ Strong  ++ Medium + Weak 
Colour: 
- No colour   Pr Purple 
O Orange   Pk Pink 
L.G Light green  L.B Light blue 
D.G Dark green  D.B D.Blue  
Y Yellow              D.BF Dark Blue Fluorescent 
OF Orange Fluorescent            PrF Purple Fluorescent 
RF Red Fluorescent 
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4.2.3 Thin Layer Chromatography (TLC) of Roots Pereskia bleo 
 
Table 4.10 showed 11 compounds were detected in root Pereskia bleo hexane crude 
extract. Thin Layer Chromatography (TLC) analysis has revealed that these compounds 
were phenol, flavonoids and terpenoid due to colour appeared after TLC plates were 
sprayed with vanillin-sulphuric acid and dragendorff reagents.  
 
In root Pereskia bleo petroleum ether crude extract, 12 compounds were revealed in 
Thin Layer Chromatography (TLC) analysis. The coloured band appeared once the TLC 
plates were sprayed with vanillin-sulphuric acid and dragendorff reagent showed the 
presence of phenol, flavonoids and terpenoid (Table 4.11). 
 
While the Thin Layer Chromatography (TLC) analyses of root Pereskia bleo 
chloroform crude extract has detected the presence of 10 compounds. These compounds 
were identified as alkaloid and terpenoid according to colour appeared after sprayed with 
vanillin-sulphuric acid and dragendorff reagents. Two unknown compounds were identified 
due to could not be detected by reagents (Table 4.12). 
 
Furthermore, 12 compounds were detected in Thin Layer Chromatography (TLC) 
analysis of roots Pereskia bleo methanol crude extract. These compounds were identified as 
alkaloid, phenol and terpenoid according to colour appeared after TLC plates were sprayed 
with vanillin-sulphuric acid and dragendorff reagents. While 2 unknown compounds were 
identified due to could not be detected by reagents (Table 4.13). 
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Table 4. 10 TLC analysis of root Pereskia bleo hexane crude extract. 
 
Labelled Rf Colour  Reagents Comment 
Compound Value 
Visible 
light 
UV light 
 
Dragendorff 
Vanillin-
H2SO4 
 
RH 1 0.971 Y+ Y++  D.G+ Pr+++ Terpenoid 
RH 2 0.929 - -  - Pr+++ Terpenoid 
RH 3 0.913  L.G+ O++  D.G++ Pk++ 
Phenol/ 
Flavonoids 
RH 4 0.797 L.G++ RF++  - Pk+ Phenol 
RH 5 0.736 L.G+ L.BF+++  - Pk++ Phenol 
RH 6 0.670 Y+ L.BF++  - Pr+++ 
Terpenoid/ 
Phenol 
RH 7 0.614 - -  - Pk+++ Phenol 
RH 8 0.550 - -  - Pr+ Terpenoid 
RH 9 0.500 - -  - P+ Terpenoid 
RH 10 0.304 Y++ -  - Pr+ Terpenoid 
RH 11 0.057 - -  - Pk+++ Phenol 
 
Indications:  +++ Strong  ++ Medium + Weak 
Colour: 
- No colour   Pr Purple 
O Orange   Pk Pink 
L.G Light green  L.B Light blue 
D.G Dark green  D.B D.Blue  
Y Yellow              D.BF Dark Blue Fluorescent 
OF Orange Fluorescent            PrF Purple Fluorescent 
RF Red Fluorescent 
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Table 4. 11 TLC analysis of root Pereskia bleo petroleum ether crude extract. 
 
Labelled Rf Colour Reagents Comment 
Compound Value 
Visible 
light 
UV light Dragendorff 
Vanillin-
H2SO4 
 
RP 1 0.993 Y++ - - Pr+++ Terpenoid 
RP 2 0.884 L.G++ OF+ L.G++ Pr++ 
Terpenoid/  
Flavonoids 
RP 3 0.819 Y+++ OF+++ - Pr+ 
Terpenoid/ 
Flavonoids 
RP 4 0.732 G+ L.BF+ - - Phenol 
RP 5 0.679 - - - Pr+ Terpenoid 
RP 6 0.594 L.G++ - - Pk+ Phenol 
RP 7 0.571 - - - Pr+++ Terpenoid 
RP 8 0.536 - - - Pr++ Terpenoid 
RP 9 0.493 L.G++ - - Pk+ Phenol 
RP 10 0.308 Y+ - - Pr++ Terpenoid 
RP 11 0.091 - - - Pr++ Terpenoid 
RP 12 0.057 - - - Pk++ Phenol 
 
Indications:  +++ Strong  ++ Medium + Weak 
Colour: 
- No colour   Pr Purple 
O Orange   Pk Pink 
L.G Light green  L.B Light blue 
D.G Dark green  D.B D.Blue  
Y Yellow              D.BF Dark Blue Fluorescent 
OF Orange Fluorescent            PrF Purple Fluorescent 
RF Red Fluorescent 
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Table 4. 12 TLC analysis of root Pereskia bleo chloroform crude extract. 
 
Labelled Rf Colour  Reagents Comment 
Compound Value 
Visible 
light 
UV light 
 
Dragendorff 
Vanillin-
H2SO4 
 
RC 1 0.884 D.G+ OF++  L.G++ -v 
Alkaloid/ 
Flavonoids 
RC 2 0.824 Y+ OF++  O++ Y+ 
Alkaloid/ 
Flavonoids 
RC 3 0.78 Y+ Y++  - Pr++ Terpenoid 
RC 4 0.614 - PR+  - - unknown 
RC 5 0.518 Y+ Y+  - Pr+++ Terpenoid 
RC 6 0.543 - -  - Pr+ Terpenoid 
RC 7 0.314 Y+ -  - - Unknown 
RC 8 0.139 Y+ L.BF+  - - Phenol 
RC 9 0.088 O++ OF+  O+ Y+ 
Alkaloid/ 
Flavonoids 
RC 10 0.037 D.G+++ OF+  D.G++ Pr++ 
Alkaloid/ 
Flavonoids/ 
Terpenoid 
 
Indications:  +++ Strong  ++ Medium + Weak 
Colour: 
- No colour   Pr Purple 
O Orange   Pk Pink 
L.G Light green  L.B Light blue 
D.G Dark green  D.B D.Blue  
Y Yellow              D.BF Dark Blue Fluorescent 
OF Orange Fluorescent            PrF Purple Fluorescent 
RF Red Fluorescent 
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Table 4. 13 TLC analysis of roots Pereskia bleo methanol crude extract. 
 
Labelled Rf Colour  Reagents Notes 
Compound Value 
Visible 
light 
UV light 
 
Dragendorff 
Vanillin-
H2SO4 
 
RM 1 0.906 D.G+++ OF++  - - Flavonoids 
RM 2 0.856 Y++ OF++  - - Flavonoids 
RM 3 0.758 - Y+  - - Unknown 
RM 4 0.66 - Pr+  - - Unknown 
RM 5 0.628 D.G++ OF+  - Pk+ 
Phenol/ 
Flavonoids 
RM 6 0.562 L.G+ OF++  - Pr+++ 
Terpenoid/ 
Flavonoids 
RM 7 0.497 D.G+ Y+  - Pr++ Terpenoid 
RM 8 0.258 O++ OF+  Pr+ Pk+ 
Phenol/ 
Flavonoids 
RM 9 0.196 Y+ Y+  - - Unknown 
RM 10 0.145 Pr+++ OF+++  O+ Pk++ 
Alkaloid 
/Flavonoids/ 
Phenol 
RM 11 0.098 D.G++ OF++  L.G+ Pk+ 
Phenol/ 
Flavonoids 
RM 12 0.058 L.G+++ OF+  L.G+ Pr++ 
Terpenoid 
Flavonoids 
 
Indications:  +++ Strong  ++ Medium + Weak 
Colour: 
- No colour   Pr Purple 
O Orange   Pk Pink 
L.G Light green  L.B Light blue 
D.G Dark green  D.B D.Blue  
Y Yellow              D.BF Dark Blue Fluorescent 
OF Orange Fluorescent            PrF Purple Fluorescent 
RF Red Fluorescent 
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4.2.4 Liquid Chromatography Mass Spectrometry combined with Mass 
Spectrometry (LCMS/MS) of Pereskia bleo Leaves. 
 
Initial investigation showed the presence of phenolics acid and flavonoids in 
aqueous crude extract of leaves Pereskia bleo. Further test was done using Liquid 
Chromatography Mass Spectrometry combined with Mass Spectrometry (LCMS/MS) has 
showed that Pereskia bleo leaves aqueous extract contained five expected chemical 
compounds which were one fatty acid (Jasmonic acid/dihydrocymellein) and four 
flavonoids (Chrysin, Apigenin based compounds, Apigenin 6 C Glucoside and Apigenin 7 
Rutinoside). 
  
In figure 4.2 showed the chromatogram of MS/MS fragmentation of Jasmonic acid 
or dihydrocymellein compound at mass spectrum 209.16 m/z. Other major peaks of m/z 
were 165.0, 149.0 and 191.0. The retention time of this compound was 2.091 minutes and 
the count per second of tallest peak was 7.3e6 cps. 
  
In figure 4.3 showed the chromatogram of MS/MS fragmentation of Chrysin 
compound at mass spectrum 253.09 m/z. Other major peaks of m/z were 165.0, 147.0, 
191.0, 209.0, 149.0, 173.0 and 161.0. The retention time and count per second of the tallest 
peak were 2.202 minutes and 6.9e6 cps. 
 
While in figure 4.4, showed the chromatogram of MS/MS fragmentation of 
Apigenin based compounds at mass spectrum 739.17 m/z. Other major peaks of m/z were 
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310.9, 576.9 and 283.0. The retention time and count per second of the tallest peak were 
2.648 minutes and 3.5e6 cps. 
  
The chromatogram of MS/MS fragmentation of Apigenin 6 C Glucoside at mass 
spectrum 431.28 m/z was showed in figure 4.5. Other major peaks of m/z were showed at 
310.9 and 283.0. While the retention time and count per second of the tallest peak was 
3.095 minutes and 2.1e7 cps. 
 
 In addition, in figure 4.6 showed the chromatogram of MS/MS fragmentation of 
Apigenin 7 rutinoside at mass spectrum 577.22 m/z. Other major peaks of m/z were showed 
at 282.9 and 310.0. While the retention time was 2.759 minutes and the count per second of 
the tallest peak was 3.1e6 cps. 
 
The detection of compounds contained in leaves Pereskia bleo aqueous crude 
extract using LCMS/MS method also showed the presence of 12 unknown compounds. 
These compounds were identified as unknown due to the standard compounds were not 
available in database system. Details MS/MS fragmentation of unknown compounds were 
showed in Appendix 
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Figure 4. 1 Full Chromatogram of LCMS/MS of Pereskia bleo leaves aqueous extract. 
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Figure 4.2 Full chromatogram of LCMS/MS Jasmonic acid or dihydroxymellein from Pereskia bleo leaves aqueous extract. 
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Figure 4. 3 Full chromatogram of LCMS/MS chrysin from Pereskia bleo leaves aqueous extract. 
 
 
 
 
  
 
73 
 
 
 
Figure 4. 4 Full chromatogram of LCMS/MS apigenin based compounds from Pereskia bleo leaves aqueous extract. 
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Figure 4. 5 Full chromatogram of LCMS/MS Apigenin 6 C glucoside from Pereskia bleo leaves aqueous extract. 
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Figure 4. 6 Full chromatogram of LCMS/MS apigenin 7 rutinoside from Pereskia bleo leaves aqueous extract. 
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4.2.5 Liquid Chromatography Mass Spectrometry combined with Mass 
Spectrometry (LCMS/MS) of Pereskia bleo Stems. 
 
Initial investigation of aqueous crude extracts from stems Pereskia bleo has 
detected the presence of phenolics and flavonoids compounds. Liquid Chromatography 
Mass Spectrometry combined with Mass Spectrometry (LCMS/MS) analysis showed the 
MS spectrum of stems Pereskia bleo aqueous crude extract contained  three expected 
compounds which were  2 phenolics compound (phenolics acid and 3,30-di-O-methyl 
ellagic acid) and amino acid (Tryptophan). 
 
Figure 4.8 showed chromatogram of MS/MS fragmentation of Phenolics Acid 
compound at mass spectrum 243.13 m/z. Other major peaks of m/z were 136.0 and 199.1 
m/z. The retention time of this compound was 3.189 minutes and the count per second of 
tallest peak was 1.9e6 cps. 
 
 While in figure 4.9 showed the chromatogram of MS/MS fragmentation of 
Tryptophan at mass spectrum 203.03 m/z. Other major peaks of m/z were 116.0, 142.0, 
159.1, and 186.0 m/z. The retention time and the count per second of tallest peak were 
1.422 minutes and 2.0e6 cps. 
 
 In addition, in figure 4.10 showed the chromatogram of MSMS fragmentation of 
3,30-di-O-methyl ellagic acid at mass spectrum 329.31 m/z. Other major peaks of m/z 
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were 171.0 and 211.1 m/z. The retention time and the count per second of tallest peak were 
4.739 minutes and 1.4e7 cps. 
  
 LCMS/MS of stems Pereskia bleo aqueous crude extract also found 14 unknown 
compounds. These compounds were identified as unknown compounds due to unavailable 
data of the standard compounds in database system. Details MS/MS fragmentation of 
unknown compounds were showed in Appendix. 
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Figure 4. 7 Full Chromatogram LCMS/MS of Pereskia bleo stems aqueous extract. 
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Figure 4. 8 Full chromatogram of LCMS/MS phenolics acid from Pereskia bleo stems aqueous extract. 
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Figure 4. 9 Full chromatogram of LCMS/MS trytophan from Pereskia bleo stems aqueous extract. 
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Figure 4. 10 Full chromatogram of LCMS/MS 3,30-di-O-methyl ellagic acid from Pereskia bleo stems aqueous extract.
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4.2.6 Liquid Chromatography Mass Spectrometry combined with Mass 
Spectrometry (LCMS/MS) of Pereskia bleo Roots. 
 
Initial investigation revealed that aqueous crude extract of roots Pereskia bleo 
contained phenolics and flavonoids compounds. The further test using Liquid 
Chromatography Mass Spectrometry combined with Mass Spectrometry (LCMS/MS) 
showed the MS spectrum of Pereskia bleo roots aqueous crude extract contained 9 
expected compounds. However, these compounds were identified as unknown compounds 
due to unavailable data of the standard compounds in database system. Details MS/MS 
fragmentation of unknown compounds were showed in Appendix. 
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Figure 4. 11 Full Chromatogram LCMS/MS of Pereskia bleo roots aqueous crude extract. 
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4.3 Determination of Total Phenolics Contents. 
 
Gallic acid was used as a standard reference in order to determine the total 
phenolics contents in leaves, stems and roots Pereskia bleo crude extracts. The standard 
curve of gallic acid was prepared at five different concentrations which were 0 µg/ml, 25 
µg/ml, 50 µg/ml, 75 µg/ml, 100 µg/ml and 125µg/ml. The total phenolics contents in 
Pereskia bleo crude extracts were expressed as milligram of gallic acid equivalent (GAE) 
per gram of dry sample. 
 
 
Table 4. 14 Absorbance of gallic acid in total phenolics contents. 
 
Gallic acid Absorbance at 765nm Mean + SD 
(µg/ml) 1 2  
0 0.052 0.048 0.050+ 0.003 
25 0.440 0.452 0.446 + 0.008 
50 0.818 0.811 0.815 + 0.005 
75 1.157 1.168 1.163 + 0.008 
100 1.370 1.420 1.39 + 0.04 
125 1.727 1.721 1.720+ 0.001 
 
Absorbance was expressed as means +standard deviation (SD), n=2 
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Figure 4.12 above showed a standard curve of gallic acid with linear trend line at 
zero intercept. The equation of linear standard curve was y=0.014x, which y was a 
absorbance reading at 725nm and x was a gallic acid concentration in µg/ml. The R-
squared (r2) value was 0.982. 
 
 
 
 
Figure 4.12 Standard curve of Gallic acid (standard) in total phenolics contents. 
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Samples of leaves, stems and roots of Pereskia bleo crude extracts were prepared at 
10mg/ml concentration. Figure 4.13 showed both stems and roots of Pereskia bleo aqueous 
and chloroform crude extracts revealed a higher amount of total phenolics content. The 
stems of Pereskia bleo aqueous and chloroform crude extracts revealed the highest of total 
phenolics content with 6.06 mg GAE/g and 5.69 mg GAE/g followed by roots Pereskia 
bleo chloroform and aqueous crude extracts with 3.64 mg GAE/g and 3.51 mg GAE/g. 
While leaves of Pereskia bleo methanol showed the highest in total phenolics content with 
3.00 mg GAE/g. 
 
 
Figure 4.13 Total Phenol Content of Pereskia bleo crude extracts. 
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4.4 Determination Of Total Flavonoids Contents 
 
Quarcetin was used as a standard reference in order to determine the total 
flavonoids contents in leaves, stems and roots of Pereskia bleo crude extract. This standard 
curve of quarcetin was prepared at five different concentrations which were 0 µg/ml, 0.5 
µg/ml, 1.0µg/ml, 1.5 µg/ml, 2.0 µg/ml and 2.5µg/ml. The total of flavonoids contents in 
Pereskia bleo crude extracts were expressed as milligram of quarcetin equivalent (QUE) 
per gram of dry sample. 
 
Table 4.15 Absorbance of Quarcetinin total flavonoids content. 
 
Quarcetin 
(mg/ml) 
Absorbance at 765nm 
Mean+SD 
 
1 2 
0.0 0.008 0.012 0.01+0.003 
0.5 0.064 0.059 0.062+0.004 
1.0 0.110 0.101 0.106+0.006 
1.5 0.168 0.159 0.164+0.006 
2.0 0.202 0.215 0.209+0.009 
2.5 0.245 0.259 0.252+0.010 
 
Absorbance was expressed as means +standard deviation (SD), n=2 
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Figure 4.14 showed a standard curve of quercetin with linear trend line at zero 
intercept. The equation of linear standard curve was y=0.014x, which y was an absorbance 
reading at 725nm and x was a quercetin concentration in µg/ml. The R-squared (r2) value 
was 0.982. 
 
 
 
Figure 4.14 Standard curve of quarcetin in total flavonoids content. 
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Samples of leaves, stems and roots of Pereskia bleo crude extracts were prepared at 
10mg/ml concentration. Figure 4.15 showed chloroform, methanol and aqueous crude 
extracts of stem Pereskia bleo revealed the highest total flavonoids content with 11.07 mg 
QE/g, 8.51 mg QE/g and 7.86 mg QE/g followed by both leaves and roots of Pereskia bleo 
chloroform crude extracts with 5.2 mg QE/g and 3.40 mg QE/g. 
 
 
 
Figure 4.15 Total Flavonoids content of Pereskia bleo crude extract. 
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4.5 Brine Shrimp Lethality Assay (BSLA) 
 
The toxicity of Pereskia bleo aqueous crude extracts were investigated using Brine 
Shrimp Lethality Assay (BSLA) technique. Table 4.16 demonstrated the number of 
shrimps exposed to the Pereskia bleo aqueous crude extracts and the number of shrimp 
dead.  
 
Table 4.16 Total of shrimps dead in Pereskia bleo aqueous crude extracts. 
Concentration 
samples  
Total number of shrimp Total number of dead 
(ug/ml) Leaves Stem Root Leaves Stem Root 
10 10 10 10 2 2 2 
100 10 10 10 3 4 3 
1000 10 10 10 4 5 3 
 
The lethal dose concentration LC50 was determined using Finney program. The 
higher value of LC50 means the lower toxicity of plant crude extracts. Tables below 
showed the LC50 of leaves, stems and roots Pereskia bleo aqueous crude extracts. 
Table 4.17 Probit analysis of Pereskia bleo aqueous crude extract in BSLA. 
Sample Number of Number of Percentage LC50 95 percents 
[ug/ml] Exposed dead mortality [ug/ml] Confidence 
Leaves      
1000 10 4 40  3.83 x 10-9 – 
100 10 3 30 2.51 1.65 x 109. 
10 10 2 20   
Stem      
1000 10 5 50  7.98 x 10-7 – 
100 10 4 40 3.55 1.58 x 107. 
10 10 2 20   
Root      
1000 10 4 30  3.83 x 10-9 – 
100 10 3 30 2.51 1.65 x 109 
10 10 2 20   
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4.6 Antidiabetic Studies 
4.6.1 Glycogen Phosphorylase Inhibitor Bioassay (GP) Of Pereskia bleo Crude 
Extracts. 
 
Glipizide was used as a standard reference in glycogen phosphorylase (GP) 
inhibitory activity. This drug was used to compare the antidiabetic activity of Pereskia 
bleo with common diabetic drug used nowadays. Five different concentrations of glipizide 
were prepared at 2, 4, 6, 8, and 10µgml-1.  
 
Figure 4.16 Percentage of GP Inhibition and IC50 value of Glipizide. 
 
Figure 4.16 showed the glycogen phosphorylase activity of glipizide increased 
while the concentrations of glipizide increase. The percentage of GP inhibition at all 
glipizide concentrations showed more than 80% inhibitions. At concentration of 2 µg/ml, 4 
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µg/ml, 6 µg/ml, 8 µg/ml and 10 µg/ml, the percentage of GP inhibition were 82.8%, 
82.6%, 82.5%, 84.2% and 84.4%, respectively. 
 
Leaves, stems and roots of Pereskia bleo crude extracts were prepared and tested to 
determine the percentage inhibition of glycogen phosphorylase activity. The highest 
percentage of GP inhibition indicated that more of GP activity was inhibited by crude 
extract. Figure 4.17 showed the percentage of GP inhibitions in Pereskia bleo crude 
extracts increased while the concentrations of crude extracts increased. At concentration of 
10mg/ml Pereskia bleo crude extracts, the highest GP inhibitions in three samples of 
leaves, stems and roots crude extracts came from the methanol extracts. The highest 
percentage of GP inhibition was from roots methanol crude extract, with the percentage of 
GP inhibition was 89.9% followed by leaves methanol crude extract with percentage of GP 
inhibition was 82.3%. While stems methanol crude extracts showed percentage of GP 
inhibition was 78.3%. These percentages of GP inhibitions were compared to glipizide as a 
standard reference. 
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Figure 4.17 Percentage of GP Inhibition of Pereskia bleo crude extracts compared to Glipizide. 
 
Leaves, stems and roots of Pereskia bleo crude extracts were prepared at five 
different concentrations at 2mg/ml, 4mg/ml, 6mg/ml, 8mg/ml and 10mg/ml. The half 
maximal inhibitory activity (IC50) for each crude extracts were calculated and showed in 
Table 4.18. IC50 is important to calculate the concentration of inhibitor at half of inhibitor 
activity. This value was obtained from graph extrapolation. The IC50 of glipizide was 1.1 
µg/ml. However, the IC50 of hexane and petroleum ether for leaves, stems and roots of 
Pereskia bleo crude extracts could not be determined due to the percentage of inhibition of 
these samples did not reach 50% even at the highest concentration. Details of absorbance 
recorded for all samples and standard drug were attached in appendix. 
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Table 4.18 The IC50 for all Pereskia bleo crude extracts. 
 
Samples 
IC50 Values 
(µg/ml) 
Glipizide 1.1 
Leaves 
Hexane 
Petroleum ether 
Chloroform 
Methanol 
Aqueous 
 
- 
- 
1.4 
1.6 
2.0 
Stems 
Hexane 
Petroleum ether 
Chloroform 
Methanol 
Aqueous 
 
- 
- 
3.2 
1.6 
2.3 
Roots 
Hexane 
Petroleum ether 
Chloroform 
Methanol 
Aqueous 
 
- 
- 
2.9 
1.2 
1.9 
  
 
 
 
Figure 4.18 The percentage of GP inhibitions andIC50of Pereskia bleo leaves crude extracts 
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Figure 4.19 The percentage of GP inhibitions and IC50 of Pereskia bleo stems crude extracts . 
 
 
 
Figure 4.20 The percentage of GP inhibitions and IC50 of Pereskia bleo roots crude extracts 
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4.6.2 Glycogen Phosphorylase Inhibition Bioassay (GP) Of Pereskia bleo Fractions. 
 
The leaves, stems and roots of Pereskia bleo crude extracts were fractioned with 
column chromatography using Toluene-ethyl acetate as mobile phase in a gradient way, 
range 30:70 (v/v) in order to categorize the compounds in plant extracts based on their 
polarities. Each of fractions was prepared at 1mg/ml concentration before further tested 
with glycogen phosphorylase inhibition (GP) bioassay. Figure 4.21 to 4.35 showed 
percentage of GP inhibitions of Pereskia bleo fractions. The absorbance recorded for all 
samples and standard drug (Glipizide) was attached in appendix section. 
 
Figure 4.21 Percentage of GP Inhibitions of Pereskia bleo leaves hexane fractions 
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Figure 4.22 Percentage of GP Inhibitions of Pereskia bleo leaves petroleum ether fractions 
 
 
Figure 4.23 Percentage of GP Inhibitions of Pereskia bleo leaves chloroform fractions. 
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Figure 4.24 Percentage of GP Inhibitions of Pereskia bleo leaves methanol fractions. 
 
 
Figure 4.25 Percentage of GP Inhibitions of Pereskia bleo leaves aqueous fractions 
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Figure 4.26 Percentage of GP Inhibitions of Pereskia bleo stems hexane fractions. 
 
 
Figure 4.27 Percentage of GP Inhibitions of Pereskia bleo stems petroleum ether fractions  
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Figure 4.28 Percentage of GP Inhibitions of Pereskia bleo stems chloroform fractions . 
 
 
 
Figure 4.29 Percentage of GP Inhibitions of Pereskia bleo stems methanol fractions. 
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Figure 4.30 Percentage of GP Inhibitions of Pereskia bleo stems aqueous fractions. 
 
 
Figure 4.31 Percentage of GP Inhibitions of Pereskia bleo roots hexane 
fractions. 
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Figure 4.32Percentage of GP Inhibitions of Pereskia bleo roots petroleum ether fractions. 
 
 
Figure 4.33Percentage of GP Inhibitions of Pereskia bleo roots chloroform fractions . 
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Figure 4.34 Percentage of GP Inhibitions of Pereskia bleo roots methanol fractions. 
 
 
 
Figure 4.35 Percentage of GP Inhibitions of Pereskia bleo roots aqueous fractions. 
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4.6.3 Experimental Animals 
4.6.3.1 Acute Toxicity 
 
Both male and female of Sprague dawley (SD) rats was administrated with leaves, 
stems and roots of Pereskia bleo aqueous crude extract via intraperitoneal at doses of 
250mg/kg, 500mg/kg and 1000mg/kg. Table 4.19 showed that all samples of Pereskia bleo 
aqueous crude extracts did not show any lethality or any toxic reaction at all doses in14 
days. 
 
Table 4.19 Number of exposed and survived after administrated with Pereskia bleo 
aqueous crude extracts. 
 
Sample 
Dose 
(mg/kg) 
Number of Number of survived Toxic 
  exposed 24h 72h 14days Reactions 
Leaves 250 6 6 6 6 - 
 500 6 6 6 6 - 
 1000 6 6 6 6 - 
Stem 250 6 6 6 6 - 
 500 6 6 6 6 - 
  1000 6 6 6 6 - 
Root 250 6 6 6 6 - 
 500 6 6 6 6 - 
  1000 6 6 6 6 - 
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4.6.3.2 Oral Glucose Tolerance Test (OGTT) 
 
OGTT was performed to measure the body’s ability of SD rats to consumed 
glucose as a body’s main source of energy. SD rats were fasted overnight before 
administrated with glucose at dose 3g/kg body weight by oral gavages in oral glucose 
tolerance test (OGTT). The reductions of blood glucose levels were compared with control 
group. 
 
 
 
 
Figure 4.36 Blood glucose level of SD rats after administrated with Pereskia bleo aqueous crude 
extracts and glipizide. The sign (*) means significantly different from the control value of 
diabetic group at p < 0.05. 
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Figure 4.36 showed an increased in blood glucose level for all groups from 0 
minutes until 60 minutes. The high dose of 500mg/kg body weight for leaves, stems and 
roots of Pereskia bleo aqueous crude extracts showed a significant maximum falls of blood 
glucose levels at 120 minutes as compared to control group. The roots of Pereskia bleo 
aqueous crude extract at dose of 500mg/kg showed a significantly reduction of blood 
glucose levels at 120 minutes with 21.5% of reduction. In addition, a standard drug 
glipizide showed a maximum fall of blood glucose level with 18.3%. 
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4.6.3.3 Effect of Pereskia bleo aqueous crude extracts on blood glucose level. 
 
An alloxan-induced Sprague dawley (SD) rats with blood glucose levels more than 
200 mg/dL after 7 days were considered as diabetic and were selected for antidiabetic 
study. The hyperglyceamic effects of Pereskia bleo extracts on fasting blood glucose levels 
of diabetic induced rats were showed in Table 4.20.  There was a significantly decreased in 
blood glucose level in diabetic group as compared to normal group. While diabetic groups 
treated with leaves, stems and roots of Pereskia bleo aqueous crude extracts showed a 
significantly decreased in blood glucose level compared to diabetic control group. 
 
Table 4. 20  Effect of Pereskia bleo aqueous extracts in fasting blood glucose level of diabetic rats 
 
Groups Blood Glucose Level (mg/dL) 
 
Day 0 Day 5 Day 10 Day 15 Day 20 Day 25 
Normal Control 75±11 78.5±13 74.5+10 76.8+14 79.2+11 78+10 
Diabetic Control 284±17 312±15 359±11 375±10 385±16 380±15* 
Glipizide 3mg/kg 285+11 280+19 260 ±19 270±19 265±12 260±14* 
Leaf  250mg/kg 284±16 231+17 185+13 128±16 119±13 115±10* 
Leaf  500mg/kg 286±13 263+17 205±18 160±14 99±10 97±10* 
Stem 250mg/kg 281+11 178+13 193±11 187±14 160±12 129±11* 
Stem  500mg/kg 284±13 182+19 173±12 149±10 119±19 99±12* 
Root 250mg/kg 283+12 207+19 190±12 181±18 146±10 131±16* 
Root  500mg/kg 285±15 195+18 126±16 113±16 120±10 120±19* 
The sign (*) indicated values significantly different from diabetic control group at p < 0.05. 
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4.6.3.4 Effect of Pereskia bleo aqueous crude extracts on body weights. 
 
The hyperglyceamic effects of Pereskia bleo aqueous crude extracts on body 
weight of diabetic rats were shown in figure 4.37. There was a significantly decreased in 
body weight for diabetic rats groups treated with Pereskia bleo and glipizide (standard 
drug) as compared to diabetic control group. The group of diabetic rats treated with 
glipizide showed 51% significantly increase in body weight as compared to diabetic 
control group. The highest significant increase in body weight for diabetic rats treated with 
Pereskia bleo were from leaves at dose of 500mg/kg by 35%. 
 
 
 
Figure 4.37 Effect in body weight after administrated with of Pereskia bleo aqueous extract and 
Glipizide as standard drug. The sign (*) indicated values significantly different from diabetic 
control group at p < 0.05. 
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4.6.3.5 Effects of Pereskia bleo aqueous crude extracts on Liver Function Test 
 
Liver functions test were used to determine the normal level of ALP, ALT and AST 
contains in liver. An abnormal result of liver function test showed problems existed in the 
liver. Table 4.21 showed that the oral administrations of leaves, stems and roots of 
Pereskia bleo aqueous extracts had a significant reduction (p<0.05) on serum level of 
Alanine Transaminase (AST), Aspartate Aminotransferase (AST) and Alkaline 
phosphatase (ALP) as compared to diabetic control group. 
 
 
Table 4.21Liver functions test on diabetic rats treated with Pereskia bleo 
aqueous extracts. 
 
Sample Liver Func. Test (U/L) 
 
ALT AST ALP 
Normal Control 54±8* 40±2* 39±5* 
Diabetic Control 97±8 94±4 89±3 
Glipizide 3mg/kg 59±3* 44±5* 37+2* 
Leaf  250mg/kg 52±3* 47±3* 39±4* 
Leaf  500mg/kg 59±6* 41±6* 34±6* 
Stem 250mg/kg 62±5* 44±5* 36+5* 
Stem  500mg/kg 54±9* 49±3* 36±3* 
Root 250mg/kg 58±4* 46±6* 33±6* 
Root  500mg/kg 60±6* 42±3* 32±3* 
The sign (*) indicated values significantly different from diabetic control group at p < 
0.05. 
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4.6.3.6 Effect of Pereskia bleo aqueous crude extracts on Lipid Profile Test. 
 
Lipid profile test were used to measure any abnormalities in lipid such as in 
cholesterol and triglyceride. These abnormalities identify any risk of cardiovascular 
disease, inflammation of pancreas (pancreatitis) or other diseases. Table 4.27 showed the 
triglycerides (TRIG), total cholesterol (T.CHOL) and low-density lipoprotein (LDL) level 
in alloxan-induced diabetic SD rats treated with Pereskia bleo aqueous crude extracts 
significantly (p<0.05) decreased as compared to diabetic control group. While high-density 
lipoprotein (HDL) level showed significantly (p<0.05) increased as compared to diabetic 
control group. 
 
Table 4.22 Lipid Profile Test on diabetic rats treated with Pereskia bleo 
aqueous crude extracts. 
 
Sample Lipid Profile Test (mmol/L) 
 
TRIG T.CHOL HDL LDL 
Normal Control 0.7±0.05* 1.5±0.2* 1.3±0.1* 0.5±0.1* 
Diabetic Control 1.9±1 2.3±0.1 0.5±0.1 1.1±0.1 
Glipizide 3mg//kg 0.5±1* 1.5+0.2* 1.5+0.1* 0.3+0.1* 
Leaf  250mg/kg 0.6±0.1* 1.7±0.3* 1.9±0.1* 0.6±0.1* 
Leaf  500mg/kg 0.4±0.1* 1.6±0.1* 1.2±0.2* 0.5±0.2* 
Stem 250mg/kg 0.6±0.1* 1.7±0.3* 1.9±0.1* 0.6±0.1* 
Stem  500mg/kg 0.6±0.1* 1.6±0.1* 1.1±0.2* 0.5±0.1* 
Root 250mg/kg 0.7±0.1* 1.8±0.1* 1.8±0.1* 0.7±0.1* 
Root  500mg/kg 0.6±0.2* 1.5±0.1* 1.8±0.1* 0.5±0.1* 
The sign (*) indicated values significantly different from diabetic control group at p 
< 0.05. 
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4.6.3.7 Effect of Pereskia bleo aqueous crude extracts on Renal Function Test 
 
Renal functions test were used to detect any renal disease and define the clinical 
state of renal dysfunction. Table 4.23 showed the creatinine and urea levels in alloxan-
induced diabetic rats increased significantly (p<0.05) as compared with normal control 
group. Whereas, the alloxan-induced diabetic groups treated with leaves, stems and roots 
of Pereskia bleo aqueous crude extracts and glipizide as a standard drug showed a 
significant (p<0.05) decreased in creatinine and urea levels as compared with the diabetic 
group. 
 
Table 4.23 Creatinine and urea levels on diabetic rats treated with Pereskia bleo 
extracts and Glipizide as a standard drug. 
  
Sample Renal Functions Test 
 
Urea 
(mmol/L) 
Creatinine 
(umol/L) 
Normal Control 3.7+0.8 37+2 
Diabetic Control 9.5+3 99+7 
Glipizide 3mg/kg 3.2+0.7 29+5.8 
Leaf  250mg/kg 3.9+0.4 41+3 
Leaf  500mg/kg 3.2+0.6 34+2 
Stem 250mg/kg 4.1+1 42+3 
Stem  500mg/kg 3.6+0.6 37+6 
Root 250mg/kg 4.8+0.7 33+5 
Root  500mg/kg 4.5+0.5 32+6 
 
 
 
 
 
 
 
114 
 
Samples of Pereskia bleo were prepared by dried it under room temperature. The 
dried samples were then grinded to become powder. An extraction is a processes that are 
widely used to obtain crude extract contain bioactive compounds of plants samples 
(Chirinos et al., 2007). In this study, a serial of extensive extraction method was used 
involving the extractions with non-polar solvent (hexane) to more polar solvent (methanol) 
to ensure a wide polarity range of bioactive compounds could be extracted. For aqueous 
extraction, it was done by soaking in aqueous bath at room temperature for 3 hours. The 
extracts obtained recorded as in Table 4.1. During the extraction, temperature is one of the 
most important factors to control as different bioactive compound has different stability 
that easily affected by temperature. To avoid from loss of these active compounds due to 
thermal decomposition, the temperature was carefully controlled and maintain the 
optimum temperature which is 40oC. Other factors that are important in order to get a 
quality extracted bioactive compounds were the type and concentration of solvent, size of 
plant samples, pH and extraction time (Liyana-Pathirana, 2005). The leaves, stems and 
roots of Pereskia bleo crude extracts were then evaporated to dryness under reduced 
pressure to give solid residues and further stored at -20oC for subsequent experiment. 
These extracts were standardized prepared at 10mg/g to ensure the same amount of 
bioactive compounds presence during every test. 
 
Separation and detection of chemical compounds were carried out using thin layer 
chromatography (TLC). TLC is one of the chromatography separation methods that are 
useful to separate various bioactive compound based on polarity or size. It is a common 
natural product analysis, stability test of samples and sample quality control (Cimpoiu, 
2006). This method also was the simplest and inexpensive compared to other 
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chromatography method (Nyiredy, 2001).The different ratio of mobile phase are important 
to produced solvents at varied polarities, thus allowed the different polarities of 
compounds to flows up on the TLC plate surface by capillary action at different rate. The 
compounds that are more soluble to solvent will travel faster as compared to less soluble 
compounds. In this study, the separations of bioactive compound were initially done by 
using combinations of toluene and ethyl acetate (30:70), Toluene:ethyl acetate (7:93) and 
Methanol:Chloroform (1:9) as a mobile phase. All three mobile phases showed the same 
presence of chemical compounds. But only Toluene:ethyl acetate (30:70,) was showed the 
highest total of separated bands presences in each samples after tested. Thus this 
combination was selected as a mobile phase for further test. The separated bands of 
compounds were observed under visible light. The specific classes of each bands were 
determined by sprayed the TLC plates with two chromogenic spray reagents; vanillin-
sulphuric acid and dragendorff reagents. Sometimes, bioactive compounds have a same 
colour and Rf values. Therefore, these reagents are very useful as alternative bioactive 
compound indicators. Rf (retardation factor) values are a measurement of flow rate of 
compounds. It is the relative distance of compound had travel along TLC plate surface 
relative to distance of mobile phase had travel. Visualization of TLC plate under UV light 
showed flavonoids compounds present in orange-yellow colour and phenolics compounds 
present in blue fluorescent colour (Males et al., 2001). In dragendorff reagent, the presence 
of alkaloid compound was identified by the development of orange colour. While in 
vanillin-sulphuric acid reagent, the presence of terpenoid compound was identified by the 
development of purple colour and phenols compound by red or other colours (Mehri et al., 
2011). The TLC analysis has revealed that terpenoid was detected in all crude extracts of 
Pereskia bleo leaves, stems and roots. Leaves of Pereskia bleo extracts showed the 
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presence of alkaloid compounds in hexane, petroleum ether, chloroform and methanol 
extract. Phenolics compound was detected in hexane, chloroform and methanol extract. In 
addition, flavonoids was detected in petroleum ether, chloroform and methanol extract 
(Table 4.2, Table 4.3, Table 4.4 and Table 4.5). Stems of Pereskia bleo extracts showed the 
presence of alkaloid in hexane, petroleum ether and chloroform extract. Phenol was 
detected in hexane and chloroform extracts, while flavonoids were detected in hexane and 
petroleum ether extract (Table 4.6, Table 4.7, Table 4.8, and Table 4.9). Roots of Pereskia 
bleo extracts showed the presence of alkaloid in chloroform and methanol extracts. Phenol 
was detected in hexane, petroleum ether and methanol extracts, while flavonoids was 
detected in all crude extracts (Table 4.10, Table 4.11, Table 4.12 and Table 4.13).  
 
Liquid Chromatography Mass Spectrometry combined with Mass Spectrometry 
(LCMS/MS) is frequently used in many drug developments such as in natural product, 
impurity identifications, in vivo drug screening and many more (Mike et al., 1999). It is a 
useful technique that has highly sensitivity and selectivity in detection and identification of 
chemical compounds. Moreover, this technique helps in the determination of chemical 
compound structure based on its fragmentation. In this study, LCMS/MS analysis was 
conducted on an AB Sciex 3200QTrap mass spectrometer. The full scan was done to 
evaluate the unknown compounds targets. Thus, the collision energy used was in range of 
35eV +/- 15eV. Initial investigation using LCMS/MS showed all leaves, stems and roots of 
Pereskia bleo aqueous extracts contained high amount of phenolics acid and flavonoids 
compounds. These results were in agreement with the results obtained from total phenolics 
and total flavonoids contents test. The LCMS/MS results showed that eight compounds 
were detected in Pereskia bleo aqueous extracts which were apigenin based compounds, 
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apigenin 7 rutinoside, Apigenin 6 C glucoside, chrysin, jasmonic acid or 
dehydrocymellein, dimenthyl ellagic acid, tryptophan and phenolics acid. Whereas, other 
33 compounds were detected but classified as unknown compounds due to the unavailable 
reference data in databases. All the observed known and unknown compounds were 
determined based on journal reference and ACD/Labs advanced chenometrics mass 
fragmentations predictive software. The unknown compounds were classified as unknown 
due to the data were not available in database. Further confirmation can be done for 
compounds presence usig reference standard or complementary data from various 
analytical instumentations in future. Chromatogram and spectrum mass of Pereskia bleo 
aqueous extracts were showed in Figure 4.1 to Figure 4.11. 
 
In previous research of phytochemical study reported by Doetsch (1980) using 
GCMS analysis, Pereskia bleo was claimed to contained alkaloids (3,4-dimenthoxy-β-
phenethylamine, mescaline,3-methoxytyramine and tyramine). Sri Nurestri (2008 & 2009) 
reported the presence of phytol, phenolics (α-tocophrol and 2,4-di-tert-butylphenol), 
dihydroactinidiolide and sterols (campesterol, stigmasterol, and β-sitosterol) in Pereskia 
bleo. The previous study reported that β-sitosterol, vitamin E (Sri-Nurestri et al., 2008), 
phytone (Uechi et al., 2007), 2,4-ditert-butylphenol (Kamitori et al., 1984), methyl 
palmitate, and methyl oleate (Sri Nurestri et al.,  2009) were found in Pereskia grandifolia. 
In this study, the TLC analysis showed presence of alkaloid, phenol, terpenoid and 
flavonoids while in LC-MS/MS analysis showed presence of fatty acid, flavonoids and 
phenolics compounds in Pereskia bleo extracts. The results showed not correlated with the 
previous research, therefore further confirmations of chemical compounds detected in 
Pereskia bleo extracts should be done in future. A bioassay guided fractionation may be 
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useful to isolate the bioactive compounds from the extract. It will be more definitive if 
identification of isolated compounds analysed by LC-MS/MS combined with Nuclear 
Magnetic Resonance Spectroscopy. 
 
Oxidative stress can cause a various chronic disease such as diabetes, 
cardiovascular, cancer and other diseases (Simonian et al., 1996). In diabetes, the 
pathogenesis of diabetic complication is associated with a higher oxidative stress (Baynes, 
1991). Oxidative stress through the production of reactive oxygen species (ROS) leads to 
the damage to the pancreatic β cell, development of insulin resistance, impaired glucose 
tolerance and type 2 diabetes mellitus (Ceriello et al., 2004; Wright-JR et al., 2006). 
Antioxidant compounds such as polyphenol and flavones have ability to prevent or reduce 
the mechanism of molecules oxidation by removing free radicals and blocking others by 
oxidized themselves (Behnaz et al., 2012). The previous studied also showed that the 
flavonoids and terpenes compounds isolated from medicinal plants found to stimulate 
secretion or possess an insulin like-effect (Marles et al., 1995). Flavonoids are known to 
regenerate the damaged β cells in alloxan induced diabetic rats and acts as insulin 
secretagogues (Alagammal et al., 2012). Besides, the flavonoids and phenolics compounds 
have been reported acts as scavengers of singlet oxygen and free radicals (Abu et al., 2010; 
Aparna et al., 2013). Thus, these compounds are important to protect the body damage 
caused by oxidative stress due to free radical release. In this study, the total phenolics 
content and flavonoids contents in Pereskia bleo extracts was revealed quantitatively. The 
phenolics contents were expressed as mg gallic acid equivalent (GAE) per gram of dry 
sample. The highest of phenolics contents in leaves Pereskia bleo extracts was found in 
methanol extract, 3.0+0.2 mg GAE/g. Stems extracts showed the highest phenolics 
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contents was from aqueous extract by 6.06+ 0.1 mg GAE/g. Whereas in root extracts, the 
highest phenolics contents showed in chloroform extract by 3.64+4 mg GAE/g (Figure 
4.13). The flavonoids contents were expressed as mg quarcetin equivalent (QUE) per gram 
of dry sample. Results showed that the highest flavonoids contents in leaves, stem and 
roots of Pereskia bleo extracts were from chloroform extract which were 5.2+0.7 mg 
QE/g, 11.07+0.2 mg QE/g, and 3.4+0.1 mg QE/g respectively (Figure 4.15). The finding 
are in agreement with the previous studies which Pereskia bleo extracts was also reported 
to have phenolics and flavonoids compound such as catechin, quarcetin, epicatechin, 
myricetin (Behnaz et al., 2012), α-tocophrol and 2,4-di-tert-butylphenol (Sri Nurestri et al., 
2009).This plant also reported to contained high phenolics contents that contributed to 
antioxidant (Sim et al., 2010). 
 
Brine shrimp lethality bioassay method was performed according to Meyer method 
(Sirintorn et al., 2004) and was carried out to investigated the toxicity of plant extracts. 
The method has been applied to plant extracts in order to facilitate the isolation of 
biologically active compound. The LC50 values of different Pereskia bleo aqueous extracts 
with 90% confident intervals are showed in Table 4.17. Low LC50 values indicated that the 
extracts are biologically active. The stems aqueous extract showed LC50 value was 3.55 
µg/ml. Whereas both leaves and roots of Pereskia bleo aqueous extracts showed the LC50 
values was 2.51 µg/ml. No mortality occurred in the control group. However, there is no 
comparison was made between the plant samples and other compounds. Further 
confirmations of toxicity level of Pereskia bleo extracts using other compound such as 
glipizide as a standard drug should be done in future.  
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Until now, there is no other scientific research was done on Pereskia bleo extracts 
as anti-hyperglyceamic agents. In this study, the anti-hyperglycaemic activity of Pereskia 
bleo extracts from leaves, stems and roots were evaluated through glycogen phosphorylase 
inhibition activity in Sprague dawley (SD) rats according to the method described by 
Essam, (2012) and Baginsky, (1974) with slightly modifications. The inhibition of this 
enzyme has been proposed in treating diabetes mellitus (Somsak et al., 2003). This enzyme 
was important in glycogenolysis pathway by breakdown of glycogen by phosphorylase to 
glucose-1-phosphate and glucose (Essam et al., 2012). Glucose-1-phosphate was then 
degraded by glycogen phosphorylase released phosphate and the absorbance of this 
substrate was measured at 655nm. The results showed the absorbance of solutions were 
increased proportional to the activity of this enzyme. In this study, result showed the 
leaves, stems and roots of Pereskia bleo extracts have inhibition of glycogen 
phosphorylase (GP) activity. The anti-hyperglycaemic activities of Pereskia bleo extracts 
were compared with glipizide as a standard reference drug. The percentage of GP 
inhibition in glipizide was 84.4%.At the concentration of 10mg/ml, the highest of GP 
inhibitions in leaves of Pereskia bleo extracts was from methanol extract with 82%, 
followed by aqueous extract 80%, chloroform extract 77%, hexane extract 38% and 
petroleum ether extract 14%. The highest of GP inhibitions in stems of Pereskia bleo 
extracts were from methanol extract with 78%, followed by aqueous extract 59%, 
chloroform 56%, hexane 16% and petroleum ether extract 16% respectively. Whereas, in 
root of Pereskia bleo extracts, the highest of GP inhibitions was also indicated from 
methanol extract which was 90%, followed by aqueous extract 79%, chloroform extract 
78%, hexane extract 21% and petroleum ether extract 16% respectively. 
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The half maximal inhibitory concentration (IC50) was evaluated in order to compare 
the effectiveness of plants extracts at a half of inhibitory activity. Pereskia bleo crude 
extracts were prepared at five different concentrations which were 20 mg/ml, 40mg/ml, 
80mg/ml and 100mg/ml. Table 4.18 showed the IC50 of glipizide and Pereskia bleo crude 
extracts. The IC50 of Glipizide was 1.1µg/ml. While the IC50 of hexane and petroleum ether 
in leaves, stems and roots of Pereskia bleo crude extracts could not be determined due to 
the percentage of GP inhibition were below 50% even at dose of 100 mg/ml. In leaves of 
Pereskia bleo extracts, the highest of GP inhibition was from chloroform extract with IC50 
1.4 µg/ml, followed by methanol crude extract 1.6 µg/ml and aqueous crude extract 
2µg/ml (Figure 4.18). In stem of Pereskia bleo crude extracts, the highest of GP inhibition 
was from methanol extract with IC50 1.6 µg/ml, followed by aqueous crude extract 2.3 
µg/ml and chloroforms crude extract3.2 µg/ml (Figure 4.19). While in roots of Pereskia 
bleo crude extracts, the highest of GP inhibition was from methanol extract with IC50 
1.2µg/ml, followed by aqueous crude extract 1.9µg/ml and chloroforms 2.9µg/ml (Figure 
4.20). 
 
The fractions of Pereskia bleo crude extracts were collected using column 
chromatography technique. Column chromatography was another useful technique in 
separation of bioactive compound. The principle of this method is the same as TLC 
technique, but the different is this technique enables separation in large quantities. In 
column chromatography, the stationary phase (silica gel) was always filled with mobile 
phase to avoid from dryness. Air bubbles trapped in dried stationary phase will cracked the 
phase and impairs the separation. The eluents were observed slowly travel through the 
column at different speeds, therefore an individual compounds were kept separately. The 
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combinations of toluene and ethyl acetate at ratio 30:70 (v/v) as a mobile phase was 
selected due to the higher amount of chemical compounds detected during TLC 
techniques. The results showed that the highest percentage of GP inhibitions and highest 
amount of chemical compounds in leaves, stems, and roots of Pereskia bleo crude extracts 
were from chloroform, methanol and aqueous extracts. The leaves of Pereskia bleo crude 
extracts showed the percentage of GP inhibition in these three extracts were 68.9%, 69.5% 
and 67% respectively (Figure 4.23 to Figure 4.25). In stems of Pereskia bleo crude 
extracts, the highest percentages of GP inhibitions were 50%, 51% and 56% respectively 
(Figure 4.28 to Figure 4.30). Whereas, in roots of Pereskia bleo crude extracts, the highest 
percentages of GP inhibitions were 55%, 67% and 49% respectively (Figure 4.33 to 
Figure4.35). Overall results of glycogen phosphorylase inhibitory bioassay in crude 
extracts and fractions collected from column chromatography indicated that chloroform, 
methanol and aqueous crude extracts were the best solvents to extract the anti-
hyperglycaemic agents in Pereskia bleo. In previous TLC results revealed that Pereskia 
bleo crude extracts contains flavonoids, terpenoid and phenol compounds. Moreover, in 
total phenolics and flavonoids contents showed the chloroform, methanol and aqueous 
crude extracts contains higher amount of phenolics and flavonoids compounds. Previous 
study also showed that phenol, terpenoid and flavonoids played important roles in the 
treatment of diabetes (Chude et al., 2001; Hassig et al., 1999; Hsu et al., 2000; Momoh et 
al., 2011). Thus, probably the insulin-like activities of these compounds contained in 
Pereskia bleo extracts may responsible for these GP inhibitions activities. 
 
The acute toxicity test is the first step on toxicological analysis of medicinal plants 
(Deciga-Campos et al., 2007).  This test was observed in non-diabetic rats administrated 
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with Pereskia bleo aqueous extracts from leaves, stems and roots. Non-toxicity test was 
experimental at doses 250 mg/kg, 500 mg/kg and 1000 mg/kg body weight during 14 days 
study period. Table 4.19 showed the results of the acute toxicity of Pereskia bleo crude 
extracts. No toxic sign such as death, distress, fearfulness, urination or defecation, pain 
response and spontaneous activities were observed. These result revealed that Pereskia 
bleo crude extracts did not cause any acute toxicity and the LC50 values of Pereskia bleo 
crude extracts was more 1000mg/kg as no death were found during experiment. Pervious 
study also reported that Pereskia bleo crude extracts were assigned to class D (LC50 > 
2000mg/kg), which is in a lowest toxicity class (Sim et al., 2010). 
 
A glucose tolerance test (OGTT) is a medicinal test to observe the fastest glucose 
taken to be cleared from blood. The change in blood glucose level in response to glucose 
load has been used in clinical for diabetes mellitus diagnosis and in research to evaluate the 
effectiveness of hypoglycaemic agents (Chutwadee et al., 2009). The administration of 
Pereskia bleo crude extracts by oral gavages 30 minutes after administrations of glucose to 
normal rats in OGTT showed improved glucose tolerance. For the first 60 minutes, the 
blood glucose level of all groups showed a significantly (p<0.05) increased higher than at 0 
minutes, but significantly (p<0.05) decreased from 60 to 120 minutes. The magnitude of 
effect also showed varied with the dose of administration. As showed in figure 4.36, at 
dose of 500mg/kg body weight of leaves, stems, and roots of Pereskia bleo crude extracts 
significantly produced a maximum fall of glucose level measured during 120 minutes 
compared to control group. The roots Pereskia bleo crude extracts (500mg/kg body 
weight) produced a highest significantly maximum fall of 21.5% at 120 minutes after 
glucose administration followed by roots aqueous crude extract (250mg/kg) 20%, stems 
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aqueous crude extract (500mg/kg) 14% and leaves aqueous crude extract (500mg/kg) 11%. 
While for stems aqueous crude extract (250mg/kg) and leaves aqueous crude extract 
(250mg/kg) showed a decreased in blood glucose levels with 9% and 3%. The glipizide as 
a standard drug showed a decreased in percentage of blood glucose level by 18%. These 
results showed that roots of Pereskia bleo aqueous extracts at both doses (250 mg/kg and 
500 mg/kg) were more effective in reducing the blood glucose level as compared to 
glipizide as a reference drug. Thus, these results revealed that Pereskia bleo aqueous 
extracts might be effective hypoglycaemic agents as glipizide. 
 
Hyperglyceamia is one of the important characteristics of diabetes mellitus. 
Alloxan is a toxic glucose analogue. It is a diabetogenic agent and widely used to induce 
diabetes in animal (Viana et al., 2004). Alloxan used to induce diabetes in rats, leading to 
the pancreatic β cells damage without affecting other islet types (Goldener et al., 1964; 
Solomon et al, 2012) resulting in decreased endogenous insulin release thus induces 
hyperglycaemia. The compounds are uptake selectively due to similarity of glucose 
structure. Diabetes then arises from the generation of cytotoxic oxygen free radicals which 
are targeting the DNA of pancreatic cell causing DNA fragmentation (Shankar et al., 
2007). In this study, the administration of Pereskia bleo aqueous extracts to alloxan-
induced diabetic rat showed that Pereskia bleo aqueous extracts contained bioactive 
compounds that reduced the blood sugar level. There was a significantly elevation in blood 
glucose level in diabetic control group as compared to normal control group (Table 4.20). 
The Pereskia bleo aqueous extracts-treated group showed reduction of blood glucose level 
significantly as compared to diabetic control group starting at day 15 treatment. On day 
25th, the treatment with glipizide as a standard drug showed decreased of blood glucose 
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level significantly by 72%.The leaves of Pereskia bleo at dose 250mg/kg and 500mg/kg 
showed the significantly rapid decreased in blood glucose level by 59% and 66%. Whereas 
the stem of Pereskia bleo at both doses showed a significantly decreased in blood glucose 
levels by 54% and 65%. While the roots of Pereskia bleo at both doses showed a 
significantly decreased in blood glucose levels by 53% and 58%. These results revealed 
that Pereskia bleo crude extracts have mechanism hyperglycaemia effects by either 
triggered the insulin secretion or by repairing the damage of pancreatic β cell. 
 
Tissue proteins are known to contribute to the body weight (Rajkumar et al., 1991). 
Decreases in body weight have been associated with diabetes mellitus due to excessive 
breakdown of tissue protein and could be due to catabolism of fats and protein (Hakim et 
al., 1997; Kamalakkannan et al., 2006). The breakdown of adipocytes and muscle tissues 
in alloxan-induce rat are due to the frequent urination and over conversion of glycogen to 
glucose (Lin et al., 2006). In this study, the decreased in body weight were observed 
during the treatment of diabetic rats with Pereskia bleo crude extracts and glipizide as a 
standard drug. Results showed the alloxan-induced diabetic rats groups treated with leaves, 
stems and roots of Pereskia bleo aqueous extracts increased significantly in body weights 
as compared to diabetic control group during 25days (Figure 4.37). The percentage of body 
weight of normal group was increased significantly 59%. While in diabetic group treated 
with glipizide showed the body weight increased by 51% significantly. The diabetic rats 
treated with leaves of Pereskia bleo aqueous extract at dose 500mg/kg showed the highest 
increased in body weight by 35% significantly followed by stems and roots of Pereskia 
bleo at dose 250mgkg by 33%, leaves (250mg/kg) by 30%, stems (500mg/kg) by 27% and 
roots (500mg/kg) by 22% significantly increased in body weight. These results revealed 
 
 
 
126 
 
that Pereskia bleo extracts may have a positive anabolic effect by reducing the 
degeneration of adipocytes and muscle tissue through enhancing in glucose metabolism. 
 
In this study, the change in concentration of hepatic enzymes such as alanine 
aminotransaminase (AST), serum aspartate aminotransaminase (AST), and alkaline 
phosphatase (ALP) was measured in normal and alloxan-induced diabetic rats during 25 
days treatment. The hepatic enzymes worked as liver maker which are associated with 
various disorders that have an effect on liver tissue function and were studied to evaluate 
the hepatic function. The increase in activities of ALP during diabetes is indicator of tissue 
damage due to toxicant (Ravikumar et al., 2010; Uboh et al., 2010). The analysis of the 
enzymes activities in blood serum was used to observed the condition of liver tissue and 
any damage occur after being exposed to certain pharmacological agent such as alloxan 
(Eze et al., 2012). In hepatocyte injury mechanism, ALP located in cytoplasm is release in 
the circulation after cellular damage due to alloxan administration. As a result, the injury of 
organelles such as mitochondria will triggered the released of soluble enzyme, ALT and 
AST (Muhammad et al., 2008; Sallie et al., 1991; Senthil et al., 2003). In the present 
study, the best way to present the anti-hyperglycaemic effects of leaves, stems and roots 
Pereskia bleo aqueous extracts were by compared with diabetic control group. In the same 
time, the results obtained were also compared with standard range of SIEMENS 
Dimension Vista® System at Laboratory Medicine of University Malaya Medical Centre. 
Normal range for each tests in liver functions test were as below.  
i. alanine aminotransaminase (Organization.) 30 – 65 IU/L 
ii. serum aspartate aminotransaminase (AST) 15 – 47 IU/L 
iii. alkaline phosphatase (ALP)   < 136 IU/L 
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Table 4.21 showed the significant increased in these liver enzymes were observed 
in diabetic control rats as compared to normal control rats. The treatment of diabetic rats 
with leaves, stems and roots of Pereskia bleo extracts and glipizide as a reference drug 
showed a significantly decreased in the liver enzymes as compared to diabetic control. 
Treatment with Pereskia bleo extracts for leaves, stems and roots extracts showed the 
decreased in ALT and AST within the normal range except for stems extract at dose of 500 
mg/kg showed higher than normal range in AST level.  Whereas for ALP level, the result 
showed all groups were within normal range. In addition, there were no significant 
differences in ALT, ALP, and AST of the diabetic rats treated with Pereskia bleo groups as 
compared to groups of normal control and diabetic rats treated with glipizide. Therefore, 
these results revealed that the activities of these enzymes in diabetic rats treated with 
Pereskia bleo groups may equivalent with the activities of liver enzymes in the glipizide 
and normal control rats groups. 
 
The measuring of creatinine and urea in blood serum is commonly used as renal 
dysfunction marker. The increase in creatinine and urea levels in blood serum indicates a 
kidney injury (Almdal et al., 1988). During renal diseases, glomerular filtration became 
weaken and lead to urea retention in blood. The creatinine is a waste product formed in 
muscle. It is transported through the bloodstream to the kidneys. The kidneys filter out and 
dispose the creatinine in urine. Thus, the abnormally high levels of creatinine  in blood is 
the evidence of kidney injury (Alagammal et al., 2012). In the present study, the anti-
hyperglycaemic effects of leaves, stems and roots of Pereskia bleo aqueous extracts were 
compared to diabetic control group. In the same time, the results obtained were also 
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compared with standard range of SIEMENS Dimension Vista® System at Laboratory 
Medicine of University Malaya Medical Centre. Normal range for renal function test as 
below: 
i. Urea  2.5 – 6.5 mmol/L 
ii. Creatinine 71 -106 µmol/L 
 
Figure 4.23 showed the levels of serum urea and creatinine in diabetic rats was 
significantly increased as compared to normal control group. The alloxan-induced diabetic 
groups treated with leaves, stems and roots of Pereskia bleo aqueous extracts showed 
significantly (p<0.05) decreased in urea and creatinine level as compared to the diabetic 
control. The treatment with Pereskia bleo extracts and glipizide showed the decreased in 
urea level within the normal range. Whereas in creatinine levels, the diabetic rats treated 
with Pereskia bleo extracts groups and glipizide showed lower than normal range. The low 
level of creatinine in serum indicates the problems with renal function. In recent study, a 
lower in serum creatinine levels may associated with  the increased risk of development of 
diabetes type 2 (Harita et al., 2009). These results revealed that the treatment with Pereskia 
bleo aqueous extracts was effective in preventing the increasing in serum urea level in 
alloxan-induced diabetic rats. However, the low levels in serum creatinine revealed that the 
Pereskia bleo aqueous extracts may leads to renal dysfunction. Since the creatinine levels 
are vary according to muscle mass and body’s size, a further test is needed to evaluate the 
renal function such as a glomerular filtration rate (GFR) and creatinine clearance rate 
(CrCl). GFR describes as the flow rate of filtered fluid through the kidney. Whereas the 
CrCl is referred as the rate of creatinine cleared in the body by the kidney. 
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Insulin is a potent inhibitor of lipolysis. When the level of insulin decreased in 
alloxan-induced diabetic rats due to β cell damage, the mobilization of free fatty acids from 
the peripheral fat deposit through the activity of hormone sensitive lipase was increase 
(Mbaka et al., 2012). Diabetes associated with alteration in plasma lipid, lipoprotein 
profile and increased the risk of coronary heart disease (Huang et al., 1988; Ime et al., 
2011). The level of lipid profile such as total cholesterol (TC), triglycerides (TG), LDL-
cholesterol and HDL-cholesterol level are always use as indicator to observe any risk in 
cardiovascular disorder such as coronary heart disease. In this study, the anti-
hyperglycaemic effects of alloxan-induced diabetic rats treated with Pereskia bleo aqueous 
extracts were compared with diabetic control group. The results obtained also were 
compared with standard range of SIEMENS Dimension Vista® System at Laboratory 
Medicine of University Malaya Medical Centre. The normal range of lipid profile as 
below: 
 
i. Triglyceride  < 0 mmol/L 
ii. Total Cholesterol < 5.2 mmol/L 
iii. LDL   < 2.59 mmol/L  
iv. HDL   > 1.1 mmol/L 
  
Table 4.22 showed the levels of plasma cholesterol, triglycerides and LDL-
cholesterol in alloxan-induced diabetic rats treated with all Pereskia bleo extracts and 
glipizide as reference drug were significantly (p<0.05) decreased as compared to diabetic 
control. Whereas the HDL-cholesterol level in plasma showed significantly (p<0.05) 
increased as compared to diabetic control. All the results for diabetic groups treated with 
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Pereskia bleo extracts and glipizide showed within the normal range in lipid profile test. 
Thus, these results revealed that Pereskia bleo extracts may prevents the risk of 
cardiovascular disease developments as it is associated with diabetes mellitus. 
 
 Therefore, finding of the study revealed that alloxan-induced diabetic rats 
administrated with Pereskia bleo leaves, stems and roots aqueous extracts showed the 
significant results in blood glucose levels, body weights, lipid profiles, and renal functions 
tests. In this context, Pereskia bleo extracts was proven to contained anti-hyperglyceamic 
agents and has the potential to become as one of the medicinal plants in treatment for 
diabetic mellitus.  
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Samples of leaves, stems, and roots of Pereskia bleo was extracted with aqueous, 
hexane, petroleum ether, chloroform and methanol solvents. Preliminary phytochemical 
investigation using TLC methods has revealed the presence of flavonoids, phenols, 
alkaloid and terpenoid compounds in Pereskia bleo extracts. Further identifications of this 
chemical compounds using LCMS/MS method has confirmed the presence of phenolics 
acid and flavonoids compounds. Eight expected chemical compounds were detected in 
leaves and stem of Pereskia bleo aqueous extracts which were Apigenin glucoside, 
Apigenin rutinoside, Apigen based compounds, Chrysin, Jasmonic acid or 
dihydrocymellein, tryptophan, dimethyl ellagic acid and phenolics acid. Whereas 33 of 
unknown chemical compounds were detected in roots Pereskia bleo aqueous extracts. 
Further confirmation of these compounds can be done using reference standard or different 
analytical instruments.  
 
The antidiabetic activity of Pereskia bleo were determined using two methods 
which were via in vitro by glycogen phosphorylase (GP) inhibitory bioassay and in vivo by 
administration of Pereskia bleo aqueous extracts to alloxan-induced diabetic rats. The 
bioassays showed the inhibitions of GP activity in both crude extracts and isolated 
compounds of Pereskia bleo aqueous extracts. The most potent inhibition of GP activity 
was determined in both chloroform extract of stems and roots with LC50 3.2 µg/ml and 2.9 
µg/ml, respectively. Followed by both aqueous extracts of stems and leaves with LC50  2.3 
µg/ml and 2.0 µg/ml, respectively. 
 
Acute toxicity test of Pereskia bleo aqueous extracts has proven that these plants 
contain non-toxic substances due to the absences of toxic sign such as death, fearfulness, 
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urination, pain response and distresses. These results were in agreement with the previous 
study reported that this plant was classified in class D, which is in lowest toxicity class. 
 
The administrations of Pereskia bleo aqueous extracts during anti-diabetic study 
showed that in glucose tolerance test (OGTT), the non-diabetic rats administrated with 
these plants showed a positive response in glucose blood level. The highest percentage of 
reduction in blood glucose level was detected in Pereskia bleo roots extracts at high doses 
(500mg/kg) which was 22% after 120 minutes glucose administrated. The percentage was 
higher than the percentage of reductions of glipizide as a reference drug which was 18%. 
 
The treatment of alloxan-induced diabetic rats with leaves of Pereskia bleo aqueous 
extract at doses of 500 mg/kg showed the most potent in decreasing the blood glucose 
level, liver functions (ALT, AST, ALP), renal function levels (urea, creatinine), lipid 
profile test (Triglyceride, total cholesterol, LDL) and increased in HDL and body weight. 
The blood glucose level during 25 days of treatment with extract of Pereskia bleo was 
significantly decreased by 66%. In body weight, alloxan-induced diabetic rats treated with 
extract of Pereskia bleo showed significantly reductions by 35%. In liver function test, the 
significantly decreased in ALT, AST and ALP of alloxan-induced diabetic rats after treated 
with leaves Pereskia bleo extracts at dose 500 mg/kg, were 46%, 50% and 56%, 
respectively. In renal functions test; urea and creatinine showed significantly decreased at 
59% and 66%, respectively. While in lipid profile, triglyceride level, total cholesterols and 
LDL were significantly decreased with 68%, 73% and 79%, respectively. Whereas, results 
showed the significantly increased in HDL level that was73% as compared to diabetic 
groups. 
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These finding suggests that the crude extracts of Pereskia bleo contains glycogen 
phosphorylase inhibitor as anti-diabetic agent. It is justified that the Pereskia bleo aqueous 
extracts had anti-glycaemia effect by reducing the blood glucose level which may trigger 
the insulin secretion. In addition, the results obtained from this study demonstrated the 
ability of Pereskia bleo extracts in preventing the loss of body weight, the damage of liver 
and kidney, and the risk of cardiovascular disease. Further research are needed to be 
carried out in order to have better understanding on the mechanism actions of the bioactive 
compounds in reducing the blood sugar levels in treatment of diabetes. 
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LCMS/MS Chromatogram 
i. LCMS/MS chromatogram for unknown chemical compounds of Pereskia bleo 
water extracts on leaves aqueous extract. 
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ii. LCMS/MS chromatogram for unknown chemical compounds of Pereskia bleo 
water extracts on stems aqueous extract. 
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iii. LCMS/MS chromatogram for unknown chemical compounds of Pereskia bleo 
water extracts on roots aqueous extract. 
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Glycogen Phosphorylase Inhibitory (GP) Bioassay 
 
i. Absorbance of standard drug Glipizide on GP inhibition bioassay. 
Sample Absorbance 
 
% of GP 
 
 
1 2 3 Averages Inhibition STDV 
Std Glipizide 
(mg/ml)       
0 0.869 0.865 0.881 0.872 0.00 0.008 
2 0.155 0.138 0.154 0.149 82.79 0.010 
4 0.144 0.155 0.153 0.151 82.60 0.006 
6 0.140 0.160 0.155 0.152 82.49 0.010 
8 0.140 0.133 0.138 0.137 84.18 0.004 
10.0 0.136 0.133 0.136 0.135 84.41 0.002 
 
ii. Absorbance of Pereskia bleo leaves extracts at five difference concentrations and 
solvents on GP inhibition bioassay. 
Leaves Absorbance Averages % GP STDV 
[mgml-1] 1 2 3 
 
Inhibition 
 
Hexane 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.511 0.538 0.540 0.530 23.46 0.016 
4 0.492 0.524 0.525 0.514 25.77 0.019 
6 0.501 0.473 0.402 0.459 33.72 0.051 
8 0.478 0.411 0.460 0.450 35.02 0.035 
10.0 0.442 0.422 0.447 0.437 36.85 0.013 
Pet ether 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.615 0.642 0.644 0.634 8.43 0.016 
4 0.622 0.593 0.620 0.612 11.61 0.016 
6 0.612 0.585 0.614 0.604 12.76 0.016 
8 0.589 0.615 0.602 0.602 13.01 0.013 
10.0 0.587 0.601 0.594 0.594 14.16 0.007 
Chloroform 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.214 0.231 0.238 0.228 67.10 0.012 
4 0.194 0.176 0.193 0.188 72.88 0.010 
6 0.183 0.172 0.175 0.177 74.47 0.006 
8 0.150 0.166 0.163 0.160 76.93 0.009 
10.0 0.124 0.122 0.131 0.126 81.84 0.005 
 
 
 
 
 
166 
 
‘Continued’ 
Leaves Absorbance Averages % GP STDV 
[mgml-1] 1 2 3 
 
Inhibition 
 
Methanol 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.284 0.284 0.253 0.274 60.45 0.018 
4 0.204 0.231 0.225 0.220 68.21 0.014 
6 0.173 0.178 0.182 0.178 74.33 0.005 
8 0.142 0.146 0.146 0.145 79.09 0.002 
10.0 0.149 0.132 0.141 0.141 79.67 0.009 
Water 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.321 0.350 0.349 0.340 50.87 0.016 
4 0.230 0.231 0.199 0.220 68.21 0.018 
6 0.174 0.176 0.177 0.176 74.61 0.002 
8 0.163 0.165 0.167 0.165 76.16 0.002 
10.0 0.101 0.170 0.140 0.137 80.20 0.035 
 
iii. Absorbance of Pereskia bleo stems extracts at five difference concentrations and 
solvents on GP inhibition bioassay. 
Stem 
 
Absorbance 
  
%  GP STDV 
[mgml-1] 1 2 3 Averages Inhibition 
 
Hexane 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.604 0.604 0.619 0.609 11.99 0.009 
4 0.586 0.585 0.588 0.586 15.27 0.002 
6 0.579 0.590 0.589 0.586 15.32 0.006 
8 0.578 0.580 0.581 0.580 16.23 0.002 
10 0.573 0.586 0.570 0.576 16.71 0.009 
Pet ether 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.640 0.662 0.663 0.655 5.35 0.013 
4 0.620 0.647 0.649 0.639 7.71 0.016 
6 0.634 0.623 0.630 0.629 9.10 0.006 
8 0.605 0.580 0.597 0.594 14.16 0.013 
10 0.619 0.554 0.570 0.581 16.04 0.034 
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‘Continued’ 
Stem 
 
Absorbance 
  
%  GP STDV 
[mgml-1] 1 2 3 Averages Inhibition 
 
Chloroform 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.402 0.434 0.383 0.406 41.28 0.026 
4 0.326 0.349 0.345 0.340 50.87 0.012 
6 0.386 0.327 0.335 0.349 49.52 0.032 
8 0.384 0.312 0.283 0.326 52.84 0.052 
10 0.321 0.288 0.315 0.308 55.49 0.018 
Methanol 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.288 0.281 0.280 0.283 59.10 0.004 
4 0.227 0.259 0.231 0.239 65.46 0.017 
6 0.226 0.231 0.220 0.226 67.39 0.006 
8 0.194 0.177 0.180 0.184 73.46 0.009 
10 0.160 0.151 0.139 0.150 78.32 0.011 
Water 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.378 0.361 0.374 0.371 46.39 0.009 
4 0.351 0.367 0.362 0.360 47.98 0.008 
6 0.312 0.351 0.342 0.335 51.59 0.020 
8 0.291 0.278 0.279 0.283 59.15 0.007 
10.0 0.274 0.282 0.289 0.282 59.30 0.008 
 
iv. Absorbance of Pereskia bleo roots extracts at five difference concentrations and 
solvents on GP inhibition bioassay. 
Root 
 
Absorbance 
 
Average % STDV 
[mgml-1] 1 2 3 
 
Inhibition 
 
Hexane 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.698 0.626 0.603 0.642 7.18 0.050 
4 0.533 0.639 0.555 0.576 16.81 0.056 
6 0.509 0.567 0.568 0.548 20.81 0.034 
8 0.549 0.573 0.509 0.544 21.44 0.032 
10 0.575 0.509 0.546 0.543 21.48 0.033 
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‘Continued’ 
Root 
 
Absorbance 
 
Average % STDV 
[mgml-1] 1 2 3 
 
Inhibition 
 
Pet ether 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.642 0.568 0.601 0.604 12.76 0.037 
4 0.637 0.604 0.601 0.614 11.27 0.020 
6 0.605 0.671 0.558 0.611 11.66 0.057 
8 0.606 0.634 0.580 0.607 12.33 0.027 
10 0.594 0.580 0.579 0.584 15.56 0.008 
Chloroform 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.462 0.466 0.470 0.466 32.66 0.004 
4 0.204 0.207 0.210 0.207 70.09 0.003 
6 0.164 0.199 0.135 0.166 76.01 0.032 
8 0.174 0.183 0.131 0.163 76.49 0.028 
10 0.161 0.166 0.134 0.154 77.79 0.017 
Methanol 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.065 0.067 0.077 0.070 89.93 0.006 
4 0.081 0.079 0.074 0.078 88.73 0.004 
6 0.059 0.056 0.065 0.060 91.33 0.005 
8 0.068 0.066 0.066 0.067 90.37 0.001 
10 0.063 0.074 0.073 0.070 89.88 0.006 
Water 
      
0 0.693 0.706 0.681 0.693 0.00 0.013 
2 0.321 0.349 0.350 0.340 50.87 0.016 
4 0.204 0.231 0.225 0.220 68.21 0.014 
6 0.173 0.176 0.176 0.175 74.71 0.002 
8 0.163 0.173 0.159 0.165 76.16 0.007 
10.0 0.132 0.121 0.174 0.142 79.43 0.028 
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Antidiabetic Effects of Pereskia bleo extracts on Sprague dawley (SD) rats. 
 
i. Effects of Pereskia bleo water extracts on blood glucose levels 
 
GROUP NO  
Blood Glucose Leven [mg/dl) 
0 5 10 15 20 25 
Normal Control 1 87.1 78.6 73.0 66.6 68.4 71.8 
  2 75.8 89.7 65.4 99.0 89.9 94.4 
  3 85.6 65.4 83.9 68.4 63.6 68.3 
  4 68.0 85.5 85.6 75.6 79.9 87.1 
  5 56.4 88.9 61.9 64.8 62.4 70.5 
  
  
  
6 79.3 60.7 77.0 86.4 81.1 78.0 
Average 75.4 78.1 74.5 76.8 74.2 78.4 
SD 11.6 12.4 9.6 13.5 11.1 10.4 
Diabetic Control 
  
  
  
  
  
  
  
1 292.0 326.3 362.0 381.5 395.9 388.9 
2 286.0 311.8 359.1 382.4 408.0 400.4 
3 269.0 297.4 356.3 363.6 369.2 367.2 
4 289.3 317.1 352.8 380.8 393.3 384.6 
5 265.4 293.9 344.4 361.7 367.2 360.1 
6 285.2 330.5 379.6 379.1 380.1 381.7 
Average 281.2 312.8 359.0 374.9 385.6 380.5 
SD 11.1 14.9 11.8 9.5 16.2 14.7 
Glipizide  3mg/kg 1 296.9 301.6 270.0 279.2 265.8 263.6 
  2 291.3 292.7 277.4 284.4 271.4 269.7 
  3 295.1 292.7 280.1 289.9 279.2 271.4 
  4 283.5 277.1 260.7 272.4 272.9 269.2 
  5 272.0 254.8 234.5 246.1 246.9 236.7 
  
  
  
6 271.3 260.2 240.6 245.5 251.3 249.6 
Average 285.0 279.9 260.6 269.6 264.6 260.0 
SD 11.3 19.1 19.1 19.3 12.8 13.9 
Leaf 250mg/kg 
  
  
  
  
  
  
  
1 299.7 241.9 201.0 148.0 136.9 122.4 
2 292.8 249.0 196.4 139.9 129.4 127.0 
3 293.5 234.5 185.3 123.8 119.1 114.7 
4 288.3 228.2 165.8 131.4 117.0 117.2 
5 272.6 231.4 181.1 125.1 109.2 108.8 
6 258.1 200.4 178.0 100.2 100.2 97.9 
Average 284.2 230.9 184.6 128.1 118.6 114.7 
SD 15.7 16.7 12.8 16.4 13.3 10.3 
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‘Continued’ 
 
GROUP NO  Blood Glucose Leven [mg/dl)  
    0 5 10 15 20 25 
Leaf 500mg/kg 
  
  
  
  
  
  
  
1 298.2 279.9 225.1 153.2 102.5 99 
2 293.0 271.0 201.3 178.2 114.9 112 
3 289.0 261.1 228.5 149.0 98.0 98 
4 286.4 241.3 194.5 174.4 104.8 95 
5 279.7 253.2 189.7 160.1 85.4 96 
6 260.9 254.7 190.2 145.0 89.3 80 
Average 284.5 260.2 204.9 160.0 99.2 96.7 
SD 13.1 13.7 17.5 13.6 10.8 10.2 
Stem 250mg/kg 
  
  
  
  
  
  
  
1 282.9 200.0 211.1 204.4 170.6 129.1 
2 284.7 184.0 199.8 198.0 175.0 138.0 
3 276.6 178.0 181.0 173.8 159.0 126.0 
4 274.0 173.0 195.3 195.5 155.3 136.3 
5 258.9 169.0 189.0 173.7 142.0 109.8 
6 259.2 162.0 182.9 175.4 155.5 133.0 
Average 272.7 177.7 193.2 186.8 159.6 128.7 
SD 11.3 13.3 11.3 14.0 11.9 10.3 
Stem 500mg/kg 1 297.0 201.1 187.4 153.8 96.0 99 
  2 296.9 207.3 185.1 158.0 144.0 119 
  
  
  
  
  
  
3 289.2 181.7 175.8 153.9 132.0 105 
4 278.6 172.0 162.0 129.0 99.0 84 
5 270.7 170.7 164.2 152.6 129.0 97 
6 268.8 159.0 161.0 149.3 111.0 92 
Average 283.5 182.0 172.6 149.4 118.5 99.3 
SD 12.6 18.8 11.9 10.4 19.4 11.9 
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‘Continued’ 
GROUP NO 
  Blood Glucose Leven [mg/dl) 
0 5 10 15 20 25 
Root 250mg/kg 1 294.0 231.8 204.4 195.9 152.3 148.8 
  2 294.2 228.5 195.9 193.1 160.9 141.7 
  3 289.4 201.9 198.0 183.8 146.1 139.6 
  4 279.2 186.0 185.3 194.0 139.2 131.2 
  5 273.4 199.4 179.7 161.5 135.0 108.8 
  
  
  
6 265.2 196.6 174.0 154.9 140.5 113.0 
Average 282.6 207.4 189.6 180.5 145.7 130.5 
SD 11.9 18.5 11.7 17.9 9.6 16.3 
Root 500mg/kg  
  
  
  
  
  
  
  
1 299.7 217.1 137.3 119.8 129.3 136.8 
2 297.1 211.9 140.2 129.5 123.0 135.3 
3 294.0 203.4 137.1 125.0 130.8 130.5 
4 285.9 185.0 130.8 119.1 122.2 124.1 
5 273.3 178.2 115.4 96.2 107.7 96.3 
6 260.4 175.5 99.0 89.4 107.1 94.7 
Average 285.1 195.2 126.6 113.2 120.0 119.6 
SD 15.4 17.9 16.2 16.4 10.3 19.2 
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ii. Effects of Pereskia bleo water extracts on body weight change.  
 
GROUP 
  
NO 
  
   Body  weight (g)  
0 5 10 15 20 25 
Normal Control 
  
  
  
  
  
  
  
1 128 138 149 167 189 191 
2 127 137 147 154 173 197 
3 121 136 153 169 188 201 
4 115 137 148 165 170 166 
5 121 141 157 163 173 194 
6 124 144 166 175 179 219 
Average 123 139 153 166 179 195 
SD 5 3 7 7 8 17 
Diabetic Control 
  
  
  
  
  
  
  
1 116 123 121 106 97 86 
2 121 130 142 139 121 110 
3 110 117 116 123 114 111 
4 127 128 113 104 96 99 
5 114 118 111 105 104 97 
6 103 107 109 112 89 79 
Average 115 121 119 115 104 97 
SD 8 8 12 14 12 13 
Glipizide 3mg/kg 
  
  
  
  
  
  
  
1 135 158 173 174 180 182 
2 120 131 140 147 148 179 
3 125 135 149 163 172 177 
4 116 170 191 201 212 211 
5 118 125 147 158 163 178 
6 151 167 198 216 228 231 
Average 127 148 166 176 184 193 
SD 13 19 24 27 30 23 
Leaf 250mg/kg 
  
  
  
  
  
  
  
1 125 121 112 125 137 141 
2 100 135 146 149 158 163 
3 136 161 173 180 186 189 
4 131 144 155 163 169 166 
5 119 123 136 142 151 156 
6 129 126 132 136 141 144 
Average 123 135 142 149 157 160 
SD 13 15 21 20 18 17 
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‘Continued’ 
GROUP 
  
NO 
  
Body  weight (g) 
0 5 10 15 20  25 
Leaf 500mg/kg  
  
  
  
  
  
  
  
1 129 154 163 170 178 174 
2 125 126 139 144 155 166 
3 138 159 163 176 179 174 
4 106 122 136 144 151 154 
5 128 134 139 143 156 162 
6 100 117 124 139 147 152 
Average 121 135 144 153 161 164 
SD 15 17 16 16 14 10 
Stem 250mg/kg 
  
  
  
  
  
  
  
1 126 138 149 149 153 158 
2 120 123 129 135 141 148 
3 100 102 108 118 126 132 
4 108 128 134 139 145 152 
5 96 118 128 132 136 144 
6 121 129 135 149 153 156 
Average 112 123 131 137 142 148 
SD 12 12 13 12 10 10 
Stem 500mg/kg  
  
  
  
  
  
  
  
1 121 125 133 139 145 149 
2 120 123 146 151 161 164 
3 116 117 125 131 135 140 
4 135 141 153 158 166 165 
5 111 123 137 139 142 148 
6 109 116 124 129 128 137 
Average 119 124 136 141 146 151 
SD 9 9 12 11 15 12 
Root 250mg/kg 
  
  
  
  
  
  
  
1 123 129 134 139 141 146 
2 110 127 135 143 148 154 
3 108 114 128 134 144 149 
4 109 134 143 139 140 148 
5 116 127 131 148 155 161 
6 128 131 149 151 156 165 
Average 116 127 137 142 147 154 
SD 8 7 8 6 7 8 
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‘Continued’ 
GROUP 
  
NO 
  
Body  weight (g) 
0 5 10 15 20  25 
Root 500mg/kg  
  
  
  
  
  
  
  
1 154 143 141 134 128 136 
2 121 134 139 145 148 152 
3 127 133 141 147 151 157 
4 111 139 159 161 167 174 
5 124 136 139 146 151 159 
6 125 136 149 151 159 155 
Average 127 137 145 147 151 156 
SD 14 4 8 9 13 12 
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iii. Effects of Pereskia bleo water extracts on lipid profile test 
 
GROUP 
NO 
 
Liver Func. Test 
(U/L) 
Lipid Profile Test 
(mmol/L) Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
ALT AST ALP TRIG T.CHOL HDL LDL 
 
Normal Control 
 
 
 
 
 
 
 
1 64 42 45 0.717 1.600 1.200 0.410 3.90 34 
2 62 43 40 0.760 1.600 1.270 0.524 3.80 41 
3 58 39 40 0.690 1.100 1.320 0.480 4.90 36 
4 49 42 42 0.772 1.600 1.460 0.650 3.80 37 
5 45 38 31 0.752 1.600 1.210 0.440 3.10 37 
6 46 39 36 0.820 1.600 1.554 0.730 2.50 37 
Average 54 40 39 0.752 1.517 1.336 0.539 3.67 37 
SD 8 2 5 0.05 0.2 0.1 0.1 0.8 2.0 
 
Diabetic Control 
 
 
 
 
 
 
 
1 109 93 86 1.700 2.500 0.270 1.220 12.10 100 
2 105 99 86 1.620 2.300 0.590 1.321 9.60 97 
3 96 96 89 2.690 2.200 0.590 1.280 6.90 110 
4 95 91 95 1.512 2.400 0.550 1.000 6.00 98 
5 90 94 88 2.052 2.200 0.560 1.253 11.90 90 
6 88 88 87 0.820 2.300 0.520 1.010 10.70 101 
Average 97 94 89 1.732 2.317 0.513 1.181 9.5 99 
SD 8 4 3 0.6 0.1 0.1 0.1 2.6 6.5 
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‘Continued’ 
GROUP 
 
NO 
 
Liver Func. Test 
(U/L) 
Lipid Profile Test 
(mmol/L) Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
ALT AST ALP TRIG T.CHOL HDL LDL 
 
Glipizide 3mg/kg 
 
 
 
 
 
 
 
1 60 44 38 0.400 1.900 1.620 0.333 2.40 20 
2 64 45 33 0.520 1.700 1.520 0.123 3.20 32 
3 59 51 36 0.490 1.500 1.280 0.180 3.60 24 
4 55 46 38 0.460 1.500 1.610 0.321 3.10 34 
5 59 44 37 0.580 1.400 1.520 0.432 2.90 31 
6 59 36 39 0.560 1.500 1.670 0.255 4.50 34 
Average 59 44 37 0.502 1.583 1.537 0.274 3.28 29 
SD 3 5 2 0.07 0.2 0.1 0.1 0.7 5.8 
 
Leaf  250mg/kg 
 
 
 
 
 
 
 
1 49 48 37 0.470 1.500 1.900 0.710 4.60 37 
2 51 44 46 0.690 1.200 2.020 0.880 4.10 41 
3 54 51 39 0.680 1.900 2.100 0.530 3.60 46 
4 59 42 41 0.540 1.800 1.780 0.460 3.90 43 
5 48 49 35 0.740 1.900 1.840 0.710 3.40 39 
6 53 49 36 0.550 1.900 1.990 0.700 3.60 41 
Average 52 47 39 0.612 1.700 1.938 0.665 3.867 41 
SD 3 3 4 0.1 0.3 0.1 0.1 0.4 3 
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‘Continued’ 
GROUP 
 
NO 
 
Liver Func. Test 
(U/L) 
Lipid Profile Test 
(mmol/L) 
Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
ALT AST ALP TRIG T.CHOL HDL LDL 
  
 
Leaf  500mg/kg 
 
 
 
 
 
1 66 32 42 0.480 1.400 1.452 0.555 4.20 34 
2 50 42 36 0.420 1.700 1.300 0.690 3.70 34 
3 58 48 30 0.400 1.500 1.350 0.470 2.80 35 
4 64 45 24 0.440 1.500 0.900 0.524 2.70 35 
5 58 37 32 0.440 1.700 1.330 0.440 3.00 29 
6 60 40 34 0.300 1.600 0.960 0.553 3.30 35 
Average 59 41 34 0.413 1.567 1.215 0.539 3.28 34 
SD 6 6 6 0.06 0.1 0.2 0.09 0.6 2 
 
Stem 250mg/kg 
 
 
 
 
 
 
 
1 67 40 43 0.890 1.900 2.000 0.510 3.50 45 
2 63 42 38 0.660 1.600 1.945 0.630 3.90 39 
3 67 50 35 0.550 1.300 1.990 0.770 4.10 41 
4 57 49 39 0.580 1.900 2.000 0.690 4.80 43 
5 57 45 29 0.580 1.900 1.699 0.647 5.00 47 
6 63 39 32 0.590 1.400 1.921 0.642 3.50 39 
Average 62 44 36 0.642 1.667 1.926 0.648 4.13 42 
SD 5 5 5 0.1 0.3 0.1 0.09 0.6 3 
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‘Continued’ 
GROUP 
 
NO 
 
Liver Func. Test 
(U/L) 
Lipid Profile Test 
(mmol/L) Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
ALT AST ALP TRIG T.CHOL HDL LDL 
 
Stem  500mg/kg 
 
 
 
 
 
 
 
1 55 53 35 0.550 1.700 0.930 0.570 4.10 37 
2 38 51 36 0.530 1.500 1.000 0.540 3.60 40 
3 61 49 31 0.560 1.500 1.400 0.250 4.40 44 
4 62 49 41 0.750 1.500 0.900 0.580 3.30 28 
5 50 44 39 0.760 1.700 1.350 0.530 3.20 33 
6 58 48 35 0.560 1.700 1.100 0.340 2.80 42 
Average 54 49 36 0.618 1.600 1.113 0.468 3.567 37 
SD 9 3 3 0.1 0.1 0.2 0.1 0.6 6 
 
Root 250mg/kg 
 
 
 
 
 
 
 
1 51 44 27 0.883 1.800 1.741 0.620 5.90 36 
2 60 39 25 0.690 1.800 1.725 0.628 4.60 26 
3 59 42 33 0.662 1.500 1.723 0.764 3.90 40 
4 61 53 35 0.600 1.900 1.811 0.782 4.90 34 
5 60 52 41 0.650 1.800 1.711 0.540 4.10 28 
6 55 46 35 0.869 1.900 1.883 0.750 5.20 36 
Average 58 46 33 0.726 1.783 1.766 0.681 4.767 33 
SD 4 6 6 0.1 0.1 0.07 0.1 0.7 5 
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‘Continued’ 
GROUP 
 
NO 
 
Liver Func. Test 
(U/L) 
Lipid Profile Test 
(mmol/L) Urea 
(mmol/L) 
Creatinine 
(µmol/L) 
ALT AST ALP TRIG T.CHOL HDL LDL 
 
Root  500mg/kg 
1 51 45 33 0.380 1.300 0.900 0.560 4.30 35 
2 57 44 33 0.430 1.400 0.795 0.590 5.20 37 
3 63 42 35 0.480 1.400 0.855 0.550 5.10 41 
4 58 44 30 0.720 1.600 0.838 0.600 4.40 26 
5 69 37 27 0.540 1.500 0.752 0.630 3.60 29 
6 64 39 34 0.780 1.600 0.999 0.580 4.60 25 
Average 60 42 32 0.555 1.467 0.856 0.585 4.533 32 
SD 6 3 3 0.2 0.1 0.09 0.03 0.6 6 
 
 
